

**Strengthening Clinical and
Laboratory Services at the National
Referral Level to Improve HIV
Prevention, Care and Treatment in
the Republic of Zambia under the
President's Emergency Plan for
AIDS Relief (PEPFAR)**

CDC-RFA-GH15-1603

Division of Global HIV/AIDS
Center for Global Health
Centers for Disease Control and Prevention



Contents

| | |
|---|----|
| Part I. Overview Information | 1 |
| A. Federal Agency Name | 1 |
| B. Funding Opportunity Title..... | 1 |
| C. Announcement Type:..... | 1 |
| D. Agency Funding Opportunity Number..... | 1 |
| E. Catalog of Federal Domestic Assistance Number..... | 1 |
| F. Dates | 1 |
| G. Executive Summary..... | 1 |
| Part II. Full Text..... | 2 |
| A. Funding Opportunity Description | 2 |
| 1. Background:..... | 2 |
| a. Statutory Authorities..... | 3 |
| b. Healthy People 2020: | 3 |
| c. PEPFAR Priorities and Strategies..... | 3 |
| d. Other National Public Health Priorities and Strategies:..... | 4 |
| e. Relevant Work:..... | 4 |
| 2. CDC Project Description | 5 |
| a. Approach: | 5 |
| i. Problem Statement: | 15 |
| ii. Purpose | 15 |
| iii. Outcomes | 15 |
| iv. Funding Strategy | 19 |
| v. Strategies and Activities..... | 19 |
| b. Evaluation and Performance Measurement:..... | 22 |
| i. CDC Evaluation and Performance Measurement Strategy:..... | 22 |
| ii. Applicant Evaluation and Performance Measurement Plan:..... | 27 |
| c. Organizational Capacity of Awardees to Execute the Approach: | 27 |
| d. Work Plan:..... | 27 |
| e. CDC Monitoring and Accountability Approach | 27 |
| f. CDC Program Support to Awardees..... | 28 |
| B. Award Information..... | 30 |
| 1. Type of Award: | 30 |
| 2. Award Mechanism:..... | 30 |
| 3. Fiscal Year:..... | 30 |
| 4. Approximate Total Fiscal Year Funding:..... | 30 |
| 5. Approximate Total Project Period Funding: | 30 |
| 6. Total Project Period Length:..... | 30 |
| 7. Approximate Number of Awards: | 30 |
| 8. Approximate Average Award: | 30 |
| 9. Floor of Individual Award Range: | 30 |
| 10. Ceiling of Individual Award Range:..... | 30 |

| | |
|---|----|
| 11. Anticipated Award Date: | 30 |
| 12. Budget Period Length: | 30 |
| 13. Funds Tracking:..... | 30 |
| 14. Direct Assistance: | 31 |
| 15. Indirect Costs:..... | 31 |
| C. Eligibility Information..... | 31 |
| 1. Eligible Applicants: | 31 |
| 2. Special Eligibility Requirements: | 31 |
| 3. Justification for Less than Maximum Competition: | 31 |
| 4. Other: | 31 |
| 5. Cost Sharing or Matching: | 31 |
| 6. Maintenance of Effort: | 32 |
| D. Application and Submission Information..... | 32 |
| 1. Required Registrations: | 32 |
| 2. Request Application Package: | 33 |
| 3. Application Package | 33 |
| 4. Submission Dates and Times:..... | 33 |
| 5. CDC Assurances and Certifications:..... | 33 |
| 6. Content and Form of Application Submission:..... | 34 |
| 7. Letter of Intent (LOI): | 34 |
| 8. Table of Contents: | 34 |
| 9. Project Abstract Summary: | 34 |
| 10. Project Narrative: | 34 |
| 11. Work Plan: | 36 |
| 12. Budget Narrative: | 36 |
| 13. Tobacco and Nutrition Policies:..... | 37 |
| 14. Intergovernmental Review:..... | 38 |
| 15. Funding Restrictions:..... | 38 |
| 16. Other Submission Requirements: | 46 |
| E. Application Review Information | 48 |
| 1. Review and Selection Process: | 48 |
| a. Phase I Review:..... | 48 |
| b. Phase II Review:..... | 48 |
| c. Phase III Review:..... | 48 |
| 2. Anticipated Announcement and Award Dates:..... | 48 |
| F. Award Administration Information..... | 49 |
| 1. Award Notices: | 49 |
| 2. Administrative and National Policy Requirements: | 49 |
| 3. Reporting:..... | 50 |
| a. CDC Reporting Requirements: | 50 |
| b. Specific Reporting Requirements:..... | 50 |
| i. Awardee Evaluation and Performance Measurement Plan: | 50 |

| | | |
|------|---|----|
| ii. | Annual Performance Report: | 51 |
| iii. | Performance Measure Reporting: | 52 |
| iv. | Monitoring Reporting and Evaluation: | 52 |
| v. | Federal Financial Reporting: | 52 |
| vi. | Final Performance and Financial Report:..... | 52 |
| 4. | Federal Funding Accountability and Transparency Act of 2006:..... | 53 |
| 5. | Programmatic Impact Reporting and Monitoring:..... | 53 |
| 6. | Monitoring and Evaluation:..... | 54 |
| 7. | Expenditure Analysis | 54 |
| 8. | Audit, Books, and Records Clause: | 54 |
| 9. | Reporting of Foreign Taxes..... | 56 |
| 10. | Human Subjects Restrictions:..... | 57 |
| G. | Agency Contacts..... | 57 |
| H. | Other Information..... | 58 |
| I. | Glossary..... | 59 |

Part I. Overview Information

Applicants must go to the synopsis page of this announcement at www.grants.gov and click on the “Send Me Change Notifications Emails” link to ensure they receive notifications of any changes to CDC-RFA-GH15-1603. Applicants also must provide an e-mail address to www.grants.gov to receive notifications of changes.

A. Federal Agency Name

Centers for Disease Control and Prevention

B. Funding Opportunity Title

Strengthening Clinical and Laboratory Services at the National Referral Level to Improve HIV Prevention, Care and Treatment in the Republic of Zambia under the President’s Emergency Plan for AIDS Relief (PEPFAR)

C. Announcement Type:

New-Type 1

This announcement is only for non-research international activities supported by CDC. If research is proposed, the application will not be considered. Research for this purpose is defined at:

<http://www.cdc.gov/od/science/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf>.

D. Agency Funding Opportunity Number

CDC-RFA-GH15-1603

E. Catalog of Federal Domestic Assistance Number

93.067 Global AIDS program

F. Dates

1. Letter of Intent Deadline Date: N/A

Application Deadline Date: January 23, 2015, 11:59 p.m. U.S. Eastern Standard Time, on www.grants.gov

Informational conference call or pre-application workshop if held in person for potential applicants: N/A

G. Executive Summary

1. Summary Paragraph

This FOA has an ultimate goal of reducing morbidity and mortality and improving the quality of life of adults and children infected with and/or affected by HIV/AIDS. The purpose is to provide high quality comprehensive hospital based, clinical and laboratory services for in- and out-patients in Lusaka, Zambia. The awardee will provide counseling, laboratory testing, clinical care, treatment, nutritional advice and social services for adult and pediatric HIV/AIDS patients. Strategies will be implemented to reduce the risk of HIV transmission from infected persons to their sexual partners and offspring.

Furthermore, screening and treatment or prophylaxis will be provided to reduce morbidity and mortality due to tuberculosis in HIV/TB co-infected persons. The selected awardee should have a an established strong network of professional contacts in Lusaka, Zambia to ensure a continuum of care for HIV infected persons through linkages among hospital clinical services and Lusaka’s primary health care facilities and have the ability to track patients to document clinical outcomes. Additionally, the awardee will provide services for individuals who have experienced sexual gender-based violence (GBV), including child sexual abuse (CSA) and will temporarily carry out training of personnel and infrastructure

development for related forensic investigations, until completion of planned construction of a purpose built National Forensic Science Laboratory in Zambia. While implementing the program of work the awardee will support efforts of the Zambian Ministry of Health (MOH) with human resources development and improving clinical and laboratory practice both within the host institute and nationwide. The awardee will ensure equitable access by all Zambians to its hospital services and will carry our monitoring and evaluation activities to provide strategic information for program improvement and reporting.

a. Eligible Applicants: Single Eligibility

b. FOA Type: Cooperative Agreement

c. Approximate Number of Awards: 1

d. Total Project Period Funding: \$27,475,000

e. Average One Year Award Amount: \$5,495,000.00

f. Number of Years of Award: 5 Years

g. Approximate Date When Awards will be Announced: February 2015

h. Cost Sharing and /or Matching Requirement: N/A

Part II. Full Text

A. Funding Opportunity Description

1. Background:

The FOA has an overarching goal of reducing morbidity and mortality and improving the quality of life of adults and children infected with and/or affected by HIV/AIDS. The awardee will be a national tertiary referral hospital providing comprehensive services for counseling, clinical care, laboratory testing, nutritional and social services for adult and pediatric HIV/AIDS patients. It will be required to implement strategies to reduce the risk of HIV transmission and impact of HIV/AIDS on individuals and communities and assist the Zambian Ministry of Health (MOH) with human resources development, and strengthening of clinical and laboratory practice both within the host institute and nationwide. The Awardee will ensure a continuum of care through strong linkages among hospital clinical services and Lusaka’s primary health care facilities, establish systems to track patients throughout all services and document HIV clinical outcomes. The awardee will provide services for persons affected by sexual gender based violence (GBV) and will temporarily carry out related forensic investigations to aid in prosecution of perpetrators; until planned construction of a purpose built National Forensic Science Laboratory is completed by Ministry of Home Affairs, Zambia.

The United States Government (USG) and other bilateral and multilateral Cooperating Partners (CPs)/donors that operate in Zambia signed a new 5-year Mutual Accountability Framework with the MOH in 2013, through which USG and other donors engage and coordinate with the Government of the Republic of Zambia (GRZ) to strengthen the national HIV/AIDS response. The awardee selected through this FOA, will operate within the “framework” and address sustainability of programs through:

- Collaboration with MOH to provide leadership in the implementation of HIV and AIDS activities;
- Implementing HIV and AIDS services within the policy framework of the GRZ;
- Adhering to the Guiding Principles laid out in the National Health Strategic Plan (NHSP) 2011-15, National HIV and AIDS and STI Policy, national treatment protocols and technical guidelines;
- Implementing activities using GRZ structures and infrastructure and accessing community health and social support systems, as needed.

The University Teaching Hospital (UTH), is the national tertiary referral hospital, receives in- and out-

patients from the entire country, although the majority are from Lusaka province where UTH is located. UTH has a 1,863 bed capacity and has developed Pediatric and Adult Centers of Excellence for the care and treatment of HIV/AIDS patients. UTH is also the main medical and paramedical teaching and resource center in the country, and is the host institute for several national reference laboratories. Additionally the hospital hosts all the major specialist clinics and has community outreach programs that support out of hospital care for patients. UTH has a 10 year long proven track record of successful implementation of PEPFAR funded HIV/AIDS programs through two previously awarded CDC Cooperative Agreements, for which UTH fully complied with the associated technical, financial, reporting, monitoring and evaluation requirements. UTH achieved > 90% of all of its past planned targets for adult and pediatric HIV/AIDS treatment, HTC, PMTCT and HIV/TB. It is proposed that UTH continue to assist GRZ to achieve the goal of reducing morbidity and mortality and improving the quality of life for adults and children infected with and/or affected by HIV/AIDS through providing comprehensive in- and out-patient hospital and supportive services.

a. Statutory Authorities

This program is authorized under Public Law 108-25 (the United States Leadership Against HIV/AIDS, Tuberculosis and Malaria Act of 2003) [22 U.S.C. 7601, et seq.] and Public Law 110-293 (the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), and Public Law 113-56 (PEPFAR Stewardship and Oversight Act of 2013).

The President's Emergency Plan for AIDS Relief (PEPFAR) has called for immediate, comprehensive and evidence based action to turn the tide of global HIV/AIDS. The overarching purpose of this FOA is to fund activities to prevent or control disease or injury and improve health, or to improve a public health program or service. Recipients may not use funds for research. Certain activities that may require human subjects review due to institutional requirements but that are generally considered not to constitute research (e.g., formative assessments, surveys, disease surveillance, program monitoring and evaluation, field evaluation of diagnostic tests, etc.) may be funded through this mechanism.

b. Healthy People 2020:

Healthy People 2020 provides national health objectives for improving the health of all persons by encouraging collaborations across sectors, guiding individuals toward making informed health decisions, and measuring the impact of prevention activities. Additional information on Healthy People 2020 is available at <http://www.healthypeople.gov>.

c. PEPFAR Priorities and Strategies

Under the leadership of the U.S. Global AIDS Coordinator, as part of the President's Emergency Plan, the U.S. Department of Health and Human Services' Centers for Disease Control and Prevention (HHS/CDC) works with host countries and other key partners to assess the needs of each country and design a customized program of assistance that fits within the host nation's strategic plan and partnership framework.

HHS/CDC focuses primarily on two or three major program areas in each country. Goals and priorities include the following:

- Achieving primary prevention of HIV infection through activities such as expanding confidential counseling and testing programs linked with evidence based behavioral change and building programs to reduce mother-to-child transmission;
- Improving the care and treatment of HIV/AIDS, sexually transmitted infections (STIs) and related opportunistic infections by improving STI management; enhancing laboratory

diagnostic capacity and the care and treatment of opportunistic infections; interventions for intercurrent diseases impacting HIV infected patients including tuberculosis (TB); and initiating programs to provide anti-retroviral therapy (ART);

- Strengthening the capacity of countries to collect and use surveillance data and manage national HIV/AIDS programs by expanding HIV/STI/TB surveillance programs and strengthening laboratory support for surveillance, diagnosis, treatment, disease monitoring and HIV screening for blood safety; and
- Developing, validating and/or evaluating public health programs to inform, improve and target appropriate interventions, as related to the prevention, care and treatment of HIV/AIDS, TB and opportunistic infections.

In an effort to ensure maximum cost efficiencies and program effectiveness, HHS/CDC also supports coordination with and among partners and integration of activities that promote Global Health Initiative principles. As such, grantees may be requested to participate in programmatic activities that include the following activities:

- Implement a woman- and girl-centered approach;
- Increase impact through strategic coordination and integration;
- Strengthen and leverage key multilateral organizations, global health partnerships and private sector engagement;
- Encourage country ownership and invest in country-led plans;
- Build sustainability through investments in health systems;
- Improve metrics, monitoring and evaluation; and
- Promote research, development and innovation (research is not supported by this FOA).

This announcement is only for non-research activities supported by CDC. If research is proposed, the application will not be reviewed. For the definition of research, please see the CDC Web site at the following Internet address: <http://www.cdc.gov/od/science/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf>

d. Other National Public Health Priorities and Strategies:

N/A

e. Relevant Work:

N/A

| 2. CDC Project Description | | | |
|--|---|---|--|
| a. Approach: | | | |
| <u>Activities</u> | <u>Outcomes</u> | | |
| | <u>Short Term Outcomes</u> <u>(1-2 Years)</u> | <u>Intermediate Outcomes</u> <u>(3-4 Years)</u> | <u>Long Term Outcomes</u> <u>(5+ Years)</u> |
| CARE AND TREATMENT OF HIV INFECTED PERSONS | | | |
| <p>Provide comprehensive clinical management of HIV infected persons including screening and treatment for TB, sexually transmitted infections (STIs) and opportunistic infections (OIs) and antiretroviral therapy (ART) for treating eligible persons</p> <p>Evaluate HIV disease stage and initiate ART for all HIV infected persons who meet national eligibility criteria</p> <p>Perform TB syndromic screening of HIV patients, followed by laboratory confirmation and TB treatment, as needed, and provide Isoniazid prophylaxis to TB screen negative patients</p> <p>Provide cotrimoxazole (CTX) prophylaxis to HIV infected persons, according to national guidelines</p> <p>Evaluate HIV patients for STIs or OIs and treat as needed</p> <p>Strengthen linkages for patient referrals within the host facility and to named primary care facilities by providing quarterly lists of referred patients to sites and requesting feedback on referral outcome and retention of patients on ART</p> | <p>Increased number of HIV infected children initiated on ART</p> <p>Increased number of adults initiated on ART</p> | <p>Increased uptake of ART initiation among HIV infected persons</p> <p>Increased number of HIV infected persons appropriately managed and treated for TB, STIs and OIs</p> | <p>Improved virological suppression among HIV infected persons receiving appropriate clinical management and treatment</p> <p>Increased retention of patients on ART</p> |
| <p>Monitor the impact of ART on individuals through viral load (VL) testing and HIV drug resistance testing for those with suspected treatment failure</p> <p>Implement viral load (VL) testing for all persons on ART at 6 months and 12 months, and annually thereafter, and use VL test results to adjust treatment regimens, according to national guidelines</p> | <p>Increased number of HIV infected persons on ART with VL results available according to schedule</p> <p>Increased number of persons with suspected treatment failure with available HIV DR test results</p> | <p>Increased number of persons with suspected ART treatment failure on appropriate anti-retroviral (ARV) treatment regimen based on HIV DR results</p> | <p>Increased use of effective ARV treatment regimens that lead to viral suppression</p> |

| | | | |
|--|---|---|---|
| Implement HIV drug resistance (DR) testing of patients with suspected ART treatment failure | | | |
| Provide nutritional counseling, as appropriate, to HIV infected persons and their families | Increased number of HIV infected persons receiving nutritional advice and management | Reduced morbidity due to nutritional deficiencies among HIV infected persons and their families | Reduced morbidity due to nutritional deficiencies among HIV infected persons and their families |
| Assist MOH to strengthen skills of clinicians and develop guidelines to improve care and treatment of HIV/AIDS patients | Increased number of clinicians mentored in other health care facilities by Partner's staff Increased number of provinces with newly established Advanced HIV Treatment Centers to manage complicated HIV cases e.g. patients failing second line therapy, needing HIV DR testing to guide selection of ART regimen, or, with complicated co-morbidities (e.g. with advanced cardiac failure and end stage renal failure) | Increased number of HIV infected persons appropriately managed and treated | Improved virological suppression among HIV infected persons receiving appropriate clinical management and treatment Increased retention of patients on ART |
| DETECTION, CARE AND SUPPORT OF TB / HIV CO-INFECTED PERSONS | | | |
| Provide reciprocal screening for HIV and TB in respective service delivery areas Utilize manual or electronic recording systems to document and track screening, referrals, and treatment outcomes in pediatric and adult HIV and TB clinical services Strengthen linkages between HIV and TB clinical services Perform reciprocal screening for HIV and TB in respective clinical settings | Increased number of HIV infected persons screened for TB Increased number of persons with active TB disease screened for HIV | Increased case detection for TB and HIV Increased number of HIV and TB infected persons commenced on appropriate treatment | Improved TB cure rates Reduced morbidity and mortality of persons infected with TB and HIV |
| Provide TB prophylaxis or treatment for HIV infected persons | Increased number of HIV infected | Reduced cases of active | Increased TB cure |

| | | | |
|---|---|---|--|
| <p>Provide isoniazid prophylaxis for HIV infected persons with no active TB disease</p> <p>Provide TB antibiotic treatment for HIV infected persons with active TB disease</p> <p>Initiate ART treatment for HIV infected persons with active TB disease</p> | <p>persons with no active TB disease completing full course of Isoniazid prophylaxis</p> <p>Increased number of HIV infected persons with active TB initiated on TB treatment</p> <p>Increased number of persons with active TB disease initiated on ART</p> | <p>TB disease among HIV infected persons who complete a full course of Isoniazid preventive therapy</p> <p>Decreased number of TB relapses among HIV/TB co-infected persons who receive TB treatment</p> | <p>rates</p> <p>Reduced morbidity and mortality of persons infected with TB and HIV</p> <p>Reduced morbidity due to TB among HIV infected persons</p> |
| <p>Conduct TB Infection control activities to reduce the risk of nosocomial infections among patients and health care workers in pediatric and adult clinical wards and service areas</p> <p>Establish and implement a program for annual screening of health care workers for TB coupled with linkage to clinical and treatment services, as needed</p> | <p>Increased number of clinical wards and waiting area adhere to TB infection control procedures</p> <p>Increased number of health care workers assigned to HIV and TB clinical services trained in TB infection control</p> <p>Increased number of health care workers assigned to HIV and TB clinical services screened annually for TB</p> | <p>Fully functional program for screening of health care workers for TB and linkage to clinical and treatment services, as needed, in place</p> | <p>Decreased TB cases among health care workers in pediatric and adult clinical wards and service areas</p> |
| <p>PREVENTION OF MOTHER TO CHILD TRANSMISSION OF HIV/AIDS (PMTCT)</p> | | | |
| <p>Conduct HIV and STI screening for pregnant women and their partners</p> <p>Conduct staff training in STI screening and management and ART management according to national guidelines</p> <p>Establish quality assurance and reporting systems for HIV and Syphilis rapid testing in maternal, neonatal, and child health (MNCH) settings</p> <p>Design, implement, and evaluate communication and service</p> | <p>Increased number of clinicians and nurses within MNCH oriented or trained in management of STIs and HIV in infected pregnant women</p> <p>Increased number of HIV infected pregnant and breastfeeding women initiated on life-long ART according to national guidelines</p> | <p>Reduced new HIV and syphilis infection during the pregnancy and breastfeeding period among repeat attendees</p> <p>Increased number of persons receiving HIV and Syphilis testing with quality assured</p> | <p>Decreased mother-to-child transmission (MTCT) rate among ANC attendees</p> <p>Overall reduction in prevalence of new syphilis infections among repeat ANC attendees</p> |

| | | | |
|---|--|---|--|
| <p>delivery program models for enhanced male engagement within MNCH services</p> <p>Screen and treat pregnant women and their partners for HIV and STIs</p> <p>Initiate ARV treatment of HIV infected pregnant women and their treatment eligible HIV infected partners, including HIV infected male partners in discordant couples</p> | <p>Increased number of HIV infected male partners of pregnant women, including those in discordant couples, initiated on ART</p> <p>Increased number of pregnant women and their male partners with STIs receiving full treatment within antenatal care (ANC) settings</p> | <p>results</p> <p>Functional continuous quality improvement system in place</p> | |
| <p>Integrate services for HIV, Sexual Reproductive Health (SRH) and Family Planning (FP) in MNCH settings</p> <p>Train staff on SRH and FP and orient them on integration with HIV services</p> <p>Equip staff and facilities with jobs aids, tools and equipment to enable provision of integrated HIV, FP and SRH services</p> <p>Provide SRH, FP and HIV information and services to couples identified in MNCH settings</p> | <p>Increased number of all clients within MNCH receiving HIV, SRH and FP services</p> | <p>Increased integration of FP and SRH services in MNCH settings</p> | <p>Improved SRH among MNCH attendees</p> <p>MNCH attendees adopt family planning strategies to plan future pregnancies</p> |
| <p>Establish surveillance for ART toxicity in women and birth defects in infants who are exposed to Efavirenz (EFV) and Tenofovir (TDF) containing ART regimens</p> <p>Provide technical assistance to MOH for review of ART safety data in relation to recommended ART drug regimens</p> | | <p>Functional ART toxicity and birth defects surveillance programs within MNCH settings in place</p> | <p>Safety data available on EFV ART use in pregnancy</p> |
| <p>Implement a mother-baby pair tracking system to document clinical outcomes after referral to named primary care facilities</p> <p>Coordinate provision of quarterly lists of referred mother-baby pairs to named primary care facility and feedback requested on referral outcome</p> | <p>Increased number of HIV infected women and their babies retained in care throughout pregnancy up to cessation of breastfeeding</p> | <p>Continuity of care provided to HIV infected women and their babies</p> | <p>Increased documentation and better clinical outcomes for mother-baby pairs retained in care and treatment in the community</p> |
| <p>DIAGNOSIS, CARE AND SUPPORT FOR INFANTS AFFECTED BY HIV/AIDS (PDCs)</p> | | | |

| | | | |
|--|--|---|---|
| <p>Provide services for diagnosis, treatment and clinical management of HIV exposed infants</p> <p>Conduct staff training for comprehensive management of HIV exposed infants using the national ART consolidated guidelines for HIV diagnosis, treatment and prevention</p> <p>Carry out Early Infant Diagnosis (EID) tests on HIV exposed infants</p> <p>Implement ARV and CTX prophylaxis for all HIV exposed infants</p> | <p>Increased number of HIV exposed infants having all four scheduled HIV tests by age 18 months</p> <p>Increased number of all HIV exposed infants receiving ARV and Cotrimoxazole prophylaxis</p> | <p>Increased number of HIV infected infants diagnosed in a timely manner and enrolled in care and treatment services</p> | <p>Reduced HIV mortality among HIV exposed infants</p> |
| <p>Provide specialized services for assessment of and assistance to HIV exposed infants to address nutritional and developmental needs</p> <p>Assess children’s nutritional needs, and refer mothers to nutrition services for advice on infant feeding</p> <p>Assess children’s developmental delays and refer to specialist, as appropriate</p> | <p>Increased number of HIV infected children assessed and receiving support for nutritional or developmental problems as appropriate</p> | | <p>Reduced morbidity and mortality due to nutritional deficiencies and developmental delays among HIV infected infants</p> |
| <p>HIV TESTING AND COUNSELING</p> | | | |
| <p>Institutionalize Provider Initiated HIV Testing and Counseling (PITC) for all children and adults who access hospital services (in Pediatrics; Internal Medicine; Surgery; Obstetrics and Gynecology; STI, TB, antenatal clinics and out-patient department) and provide follow up services to HIV infected persons</p> | <p>Increased number of child and adult in- and out-patients with known HIV status</p> <p>Increased linkage of newly identified HIV infected persons to care and treatment</p> | <p>Increased number of child and adult in- and out-patients with known HIV status</p> <p>Increased linkage of newly identified HIV infected persons to care and treatment</p> | <p>Reduced morbidity and mortality among HIV infected persons</p> <p>Reduced HIV transmission</p> |
| <p>Strengthen couples HTC and provide follow up services</p> <p>Provide HTC to all couples identified in service delivery settings and other prevention and care services as needed</p> <p>Provide ART to HIV infected persons in HIV discordant couples</p> | <p>Increased number of couples who present at in- and out- patient services receiving PITC</p> <p>Increased number of HIV positive persons in HIV discordant couples</p> | <p>Increased referral of HIV positive persons for care and treatment to reduce transmission risk</p> | <p>Decrease in frequency of transmission in HIV discordant couples</p> <p>Reduced morbidity and mortality among</p> |

| | | | |
|---|--|--|--|
| Coordinate provision of quarterly lists of referred HIV discordant couples to named primary care facility and request feedback on referral outcome | initiated on ART | | HIV infected persons through better access to care and treatment |
| STRENGTHEN LABORATORY SERVICES | | | |
| <p>Provide on-site laboratory testing capacity for key analytes</p> <p>Perform testing for key analytes</p> <p>Use process mapping to establish realistic laboratory turnaround times, TAT (expected interval between sample collection and availability of laboratory results)</p> <p>Establish system for routine monitoring of laboratory performance against established TATs, linked to taking corrective action for results delays</p> <p>Evaluate new diagnostics for key analytes to determine suitability for use on-site or within Zambia</p> | <p>Increased monitoring of TAT for providing laboratory results for key analytes</p> | <p>Increased proportion of results provided within established TAT</p> <p>Decrease in the time taken to evaluate and bring new diagnostics into routine use for improving laboratory testing</p> | <p>Timely laboratory results available for patient care, monitoring and treatment</p> <p>Increase in the number of new diagnostics brought into routine use to improve laboratory support for patient care</p> |
| <p>Identify and resolve problems that lead to failure to provide laboratory results</p> <p>Procure, use and monitor results for Internal Quality Control (IQC) samples run when testing for key analytes</p> <p>Use trends in IQC data to trouble shoot problems with testing and take corrective action</p> <p>Establish on-going monitoring of number of days when testing cannot be performed because of reagent stockouts, equipment failure or interruption of electricity supply and use information for implementing corrective action</p> | <p>Increase in use of quality control data in determining accuracy of laboratory results</p> <p>Increased identification and resolution of problems causing disruptions of laboratory services</p> | <p>Decrease in frequency of obtaining invalid laboratory results and of discarding test runs</p> <p>Decrease in frequency of disruption of laboratory services</p> | <p>Increased operational efficiency of laboratory services</p> |
| <p>Provide Proficiency Test (PT) programs for key analytes to document accuracy of laboratory testing</p> <p>Awardee's laboratories participate in external PT programs for</p> | <p>Increased use of proficiency test results to evaluate laboratory performance</p> | <p>Increased mean scores among PT participants</p> <p>Attainment of national</p> | <p>Increase in national accuracy of laboratory testing for key analytes</p> |

| | | | |
|---|---|--|---|
| <p>key analytes</p> <p>The awardee coordinate all aspects of national PT programs for HIV RT and CD4 cell enumeration and provides feedback reports to participants and stakeholders</p> <p>The awardee coordinates a sub-national external quality assurance program for TB microscopy</p> | <p>Increased number of test sites enrolled in national PT programs for HIV RT and CD4 cell enumeration</p> <p>Increased documentation of corrective action taken with sites that provide inaccurate laboratory results</p> | <p>coverage of current PT programs for HIV RT and CD4 cell enumeration</p> <p>Increased number of analytes evaluated in PT programs</p> <p>Increased documentation of corrective action taken with sites that fail PTs</p> | |
| <p>Train laboratory personnel to perform testing for key analytes</p> <p>Assist MOH to develop and utilize standardized curricula for training of laboratory personnel</p> <p>Ensure use of pre-and post- workshop training evaluations to document gains in knowledge of trainees</p> <p>Utilize analysis of reference strains or evaluation of proficiency tests to determine the competency attained by trainees through training workshops</p> <p>Run training workshops for laboratory personnel in collaboration with CDC & MOH to strengthen laboratory services, particularly Microbiology, CD4, HIV RT, viral load testing and EID</p> <p>Train personnel and implement Strengthening of Laboratory Management Towards Accreditation (SLMTA)</p> <p>Train staff on population based surveillance that requires biomarker testing</p> | <p>Increased number of personnel with documented competency to carry out accurate testing and correctly use SOPs</p> <p>Increased involvement of laboratory personnel and services in generating strategic information about program performance</p> <p>Increased number of trained personnel in Microbiology, capacity for viral load testing, EID and other HIV/AIDs patient monitoring laboratory testing</p> | <p>Increase in the number of national test sites with capacity for testing key analytes</p> <p>Increased availability of laboratory results from surveys undertaken to provide strategic information</p> <p>Increase in the number of personnel trained in Quality management Systems and accreditation related subject matters</p> | <p>Increase in number of personnel and test sites providing accurate laboratory testing for key analytes</p> |

| | | | |
|--|---|---|---|
| <p>Conduct biologic testing of specimens collected through population-based surveys to assess HIV prevalence and incidence, HIV drug resistance, viral load, CD4 analysis, syphilis, Herpes Simplex Virus (HSV) and other biological markers, as needed</p> | | | |
| <p>REDUCTION OF IMPACT OF SEXUAL GENDER BASED VIOLENCE (GBV)</p> | | | |
| <p>Provide information and support for sexual GBV</p> <p>Provide an on-site sexual GBV and Family Support Unit to cater for the needs of children and their family members who require age appropriate evidence based psychosocial counseling, care and support because of sexual abuse</p> <p>Collaborate with Ministry of Community Development Mother Child Health (MCDMCH) and Ministry of Gender and Child Development to prepare and disseminate information on sexual GBV to key influential network groups (e.g. women’s and human rights groups, police, law association, victim support groups, medical personnel, traditional leaders, church groups)</p> <p>Monitor numbers of clients seen at sexual GBV centers and referral trends and assess the source of their knowledge about center’s services</p> | <p>Increased number of sexual GBV cases and their family members provided with knowledge/ awareness of sexual GBV and CSA</p> <p>Increased knowledge/ awareness of sexual GBV and CSA among persons in key influential networks for GBV issues</p> | <p>Increased use of cognitive behavior or other appropriate therapies to ameliorate the impact of sexual GBV</p> | <p>Reduction in the number of mental health symptoms (e.g. traumatic stress, internalizing or externalizing behavior) among sexual GBV cases</p> |
| <p>Engage stakeholders to increase the range of services that are made available to sexual GBV cases</p> <p>Collaborate with social workers, Non-governmental Organizations and government social welfare department to identify safe havens to temporarily shelter persons affected by sexual GBVs until they can be re-integrated into communities</p> <p>Provide care, temporary shelter and services (e.g. access to health, education, and psychosocial support) for CSA cases children until they can be reintegrated into communities</p> | <p>Increased number of safe havens identified for sexual GBV cases</p> <p>Increased educational and health support for child sexual GBV cases</p> <p>Increased knowledge/ awareness of sexual GBV and CSA among persons in key influential networks who can advocate for increased resources for GBV</p> | <p>Increased number of sexual GBV cases successfully reintegrated from temporary shelters into the community</p> <p>Increased supportive services available in health facilities and communities to address sexual GBV issues</p> | <p>Better care and support and more services for sexual GBV cases</p> |

| | | | |
|---|---|---|--|
| Conduct training workshops and sensitization meetings with key influential groups (e.g. women's, church, or medical professional groups, NGOs, police, social services) | related services | | |
| Scale up sexual GBV services through training of health care workers in host institute and in other locations in the country to encourage advocacy for provision of services down to community level health facilities | Increased number of health care professional provided with training on identification and reporting of sexual GBV cases | Increased integration of services for the prevention, care and management of sexual GBV cases down to primary health care facilities and in communities | Increased numbers of persons have access within their community to services for sexual GBV |
| <p>Provide medical evaluation of sexual GBV cases and establish forensic investigative capacity to aid in conviction of perpetrators of GBV</p> <p>Provide on-site or referral services for comprehensive medical evaluation of sexual GBV cases</p> <p>Leverage PEPFAR financial resources towards the establishment of a national forensic science laboratory to test samples from sexual GBV cases</p> <p>Procure equipment and train personnel in sample collection, chain of custody issues, sample archiving and DNA technologies needed to carry out forensic investigations</p> <p>Work with the Ministry of Community Development, Mother and Child Health, Ministry of Gender and Child Development, and the Victim Support Unit of the Police to strengthen national programs and training on GBV</p> <p>Use Multidisciplinary Committees to review sexual GBV cases and improve linkages between medico-legal and social service providers with police, prosecutors and community support organizations</p> | <p>Increased number of sexual GBV cases with investigation procedures expedited to enable timely initiation of HIV post exposure prophylaxis (PEP)</p> <p>Increased number of personnel receive forensic investigative training</p> <p>Functional forensic laboratory capacity established</p> | <p>Increased numbers of sexual GBV cases with forensic samples collected, tested and reported to assist with conviction of perpetrators</p> <p>Increased number of multidisciplinary Committees established that regularly meet to review and improve services for sexual GBV cases</p> | <p>Decrease in transmission of HIV due to sexual GBV</p> <p>Increased use of forensic evidence to aid in prosecution in sexual GBV cases</p> |

PROVISION OF STRATEGIC INFORMATION

| | | | |
|--|---|---|---|
| <p>Develop and implement a monitoring, evaluation and reporting plan</p> <p>Convene meeting with program coordinator and other key personnel to orient them on the PEPFAR Monitoring Evaluation and Reporting (MER) indicators</p> <p>Identify data sources, data collection strategies, and analysis plans to meet PEPFAR MER requirements and process monitoring of program implementation</p> <p>Identify data management training needs and conduct training of data clerks to fulfil data management requirements</p> <p>Assist Awardee to implement electronic based data management systems</p> <p>Incorporate data from on-going monitoring and HIV drug resistance and HIV prevalence in different clinic populations to make inferences about program progress</p> <p>Utilize routine program data for quality improvement</p> | <p>Increased number of data clerks with capacity to fulfill data management requirements</p> <p>Increased number of quality interventions implemented</p> | <p>Improved recording and reporting systems in place</p> | <p>Functional continuous quality improvement system established</p> |
| <p>Expand use of electronic health records to improve patient management, service delivery and program MER</p> <p>Establish model sites that implement e-first electronic health record (e.g. Smart Care) for all persons who access clinical services at the hospital</p> <p>Utilize electronic health records to monitor trends in service utilization (e.g. workload, laboratory and drug usage) and use data for planning</p> <p>Utilize electronic health records for routine monitoring and evaluation, semi-annual and annual program reporting</p> | <p>Increased number of pediatric and adult clients with electronic health record</p> | <p>Improved recording and reporting systems in place</p> | <p>Increased use of Smart Care data to document continuity of care for pediatric and adult HIV/AIDS clients</p> <p>Increased availability of data to monitor program impact on HIV prevalence and causes of morbidity and mortality</p> |

| |
|---|
| <p>i. Problem Statement:</p> |
| <p>High workload, diversity of clinical, nutritional and social support needs of patients, weak laboratory services, inefficiencies in some administrative and data management practices combined with inadequate allocation of national resources to meet full operational costs of the hospital, adversely impact on the quality of care of HIV/AIDS patients. Sexual gender based violence (GBV), is a significant problem in the wider society, that may contribute to HIV transmission, but there are inadequate medical services available to support victims and their families. The national referral hospital has a mandate to assist MOH with training and mentoring of health care professionals and with the development of guidelines and standards for clinical and laboratory services.</p> |
| <p>ii. Purpose</p> |
| <p>The overarching purpose of the FOA is to implement strategies at multiple service delivery points in the national tertiary referral hospital in Lusaka, Zambia. The objectives are:</p> <ul style="list-style-type: none"> • To increase the coverage of Provider Initiated Testing and Counseling at each service delivery point within UTH from about 50% to >95%. • To reduce the MTCT rate among HIV infected pregnant women managed at UTH from the current 9% to <2% by 2020. • To increase the number of Advanced Treatment Centers from one to five by 2020. • To increase coverage of Post-Exposure Prophylaxis (PEP) and psychosocial services for sexual Gender Based Violence and Child Sexual Abuse victims from 49% to 95 % by 2020. • To achieve national coverage of current Proficiency Testing programs for HIV RT and CD4 cell enumeration and increase the number of laboratories accredited to international standards by 2020. |
| <p>iii. Outcomes</p> |
| <p>The performance of the awardee of this FOA will be evaluated by comparing achievements at the end of years 1 and 5 of the project period. The outcomes to be met in each program area are as follows:</p> <p><u>CARE AND TREATMENT OF HIV INFECTED PERSONS</u></p> <p>The key expected outcomes are:</p> <p>SHORT TERM:</p> <ul style="list-style-type: none"> • Increased number of HIV infected children initiated on ART • Increased number of adults initiated on ART • Increased number of HIV infected persons on ART with viral load results available according to schedule • Increased number of persons with suspected treatment failure with available HIV DR test results • Increased number of HIV infected persons receiving nutritional advice and supplementation, as appropriate • Increased number of clinicians mentored in other health care facilities by Partner’s staff • Increased number of provinces with newly established Advanced HIV Treatment Centers through technical assistance provided by the selected Partner <p>INTERMEDIATE:</p> <ul style="list-style-type: none"> • Increased ART initiation among HIV infected persons • Increased number of HIV infected persons appropriately managed and treated for TB, STIs and OIs |

- Increased number of persons with suspected ART treatment failure on appropriate ARV treatment regimen based on HIV DR results
- Increased number of HIV infected persons appropriately managed and treated

LONG TERM:

- Improved virological suppression among HIV infected persons receiving appropriate management
- Increased retention of patients on ART
- Reduced morbidity due to nutritional deficiencies among HIV infected persons and their families

DETECTION, CARE AND SUPPORT OF HIV/TB CO-INFECTED PERSONS (HIV/TB)

The key expected outcomes are:

SHORT TERM:

- Increased number of HIV infected persons screened for TB
- Increased number of persons with active TB disease screened for HIV
- Increased number of HIV infected persons with no active TB disease completing full course of Isoniazid prophylaxis
- Increased number of HIV infected persons with active TB initiated on TB treatment
- Increased number of persons with active TB disease initiated on ART
- Increased number of clinical wards and waiting area adhere to TB infection control procedures
- Increased number of health care workers assigned to HIV and TB clinical services trained in TB infection control
- Increased number of health care workers assigned to HIV and TB clinical services screened annually for TB

INTERMEDIATE:

- Increased case detection for TB and HIV
- Increased number of HIV and TB infected persons commenced on appropriate treatment
- Reduced cases of active TB disease among HIV infected persons who complete a full course of Isoniazid preventive therapy
- Decreased number of TB relapses among HIV/TB co-infected persons who receive TB treatment

LONG TERM:

- Improved TB cure rates
- Reduced morbidity and mortality of persons infected with TB and HIV
- Reduced morbidity due to TB among HIV infected persons

PREVENTION OF MOTHER TO CHILD TRANSMISSION OF HIV/AIDS

The key expected outcomes are:

SHORT TERM:

- Increased number of clinicians and nurses within MNCH oriented or trained in management of STIs and HIV in infected pregnant women
- Increased number of HIV infected pregnant and breastfeeding women initiated on life-long ART according to national guidelines
- Increased number of HIV infected male partners of pregnant women, including those in

discordant couples, initiated on ART

- Increased number of pregnant women and their male partners with STIs receiving full treatment within ANC settings
- Increased number of all clients within MNCH receiving HIV, SRH and FP services

INTERMEDIATE:

- Reduced new HIV and syphilis infection during the pregnancy and breastfeeding period by > 80% among repeat attendees
- Increased number of persons receiving HIV and Syphilis testing with quality assured results
- Functional continuous quality improvement program for laboratory testing in place, with corrective action taken based on competency evaluations or proficiency test results
- Functional ART toxicity and Birth Defects surveillance programs within MNCH settings in place
- Continuity of care provided to HIV infected women and their babies

LONG TERM:

- Overall reduction in MTCT rate from the current 9% to <5% among ANC attendees
- Overall reduction in prevalence of new syphilis infections among repeat ANC attendees
- Improved sexual reproductive health and adoption of family planning strategies to plan future pregnancies and among MNCH attendees
- Safety data available on EFV ART use in pregnancy
- Better clinical outcomes for mother-baby pairs retained in care and treatment in the community

DIAGNOSIS, CARE AND SUPPORT FOR INFANTS AFFECTED BY HIV/AIDS (PDCS)

The key expected outcomes are:

SHORT TERM:

- Increased number of HIV exposed infants having all four scheduled HIV tests by age 18 months
- Increased number of all HIV exposed infants receiving ARV and Cotrimoxazole prophylaxis.
- Increased number of HIV infected children assessed and receiving support for nutritional or developmental problems, as appropriate

INTERMEDIATE:

- Increased number of HIV infected infants diagnosed in a timely manner and enrolled in care and treatment services

LONG TERM:

- Reduced mortality among HIV exposed infants
- Reduced morbidity and mortality due to nutritional deficiencies and developmental delays among HIV infected infants

HIV TESTING AND COUNSELING

The key expected outcomes are:

SHORT TERM:

- Increased number of adult in- and out-patients with known HIV status
- Increased number of in- and out-patient children with known HIV status
- Increased number of couples who present at in- and out- patient services receiving PITC

- Increased number of HIV positive persons in HIV discordant couples initiated on ART

INTERMEDIATE:

- Increased number of persons identified as HIV infected through PITC receiving appropriate clinical management

LONG TERM:

- Reduced morbidity and mortality among HIV infected persons
- Reduced HIV transmission

LABORATORY STRENGTHENING

The key expected outcomes are:

SHORT TERM:

- Increase in the percentage of routinely tested samples with results provided within established TAT for key laboratory analytes
- Decrease in the percentage of workdays with disruption of laboratory services for key analytes due to commodities stockouts, equipment malfunction or electricity outages;
- Increase in the number of national sites with functional viral load, EID and microbiology capacity due to Partner's training and mentoring activities
- Increased corrective action taken with sites that fail proficiency tests

INTERMEDIATE:

- Decrease in the time taken to evaluate and bring new diagnostics into routine use for improving laboratory testing
- Increase in accuracy of testing by sites enrolled in proficiency test (PT) programs;
- Increase in the number of national test sites with functional capacity to test multiple key analytes as a result of the Partner's training and mentoring activities

LONG TERM:

- Increased accuracy and timeliness of laboratory testing nationally
- Improved operational efficiency of on-site laboratory services
- Increase in the number of new diagnostics brought into routine use to improve laboratory support for patient care
- Accreditation of one or more on-site laboratories to ISO 15189 standard
- Increase availability of laboratory results to stakeholders to monitor trends in HIV incidence and infectious cause of morbidity and mortality

REDUCTION OF IMPACT OF SEXUAL GENDER BASED VIOLENCE (GBV)

The key expected outcomes are:

SHORT TERM:

- Increased number of sexual GBV cases and their family members provided with psychosocial support
- Increased number of safe havens for sexual GBV cases
- Increased education, health and psychosocial support for child sexual GBV cases
- Increased number persons who are trained to identify and report sexual GBV cases
- Increased number of sexual GBV cases with investigations expedited to enable timely (within 72 hours of sexual assault) initiation of HIV post exposure prophylaxis (PEP)

INTERMEDIATE:

- Increased use of cognitive behavior of other appropriate therapies to ameliorate the impact of sexual GBV
- Increased number of sexual GBV cases successfully reintegrated from temporary shelters into the community
- Increased integration of sexual GBV supportive services into work of community level health care facilities
- Increased numbers of sexual GBV cases with forensic samples collected, tested and reported to assist with conviction of perpetrators
- Increased number of Multidisciplinary Committees established that regularly meet and review sexual GBV cases with a view to improve services

LONG TERM:

- Reduction in the number of sexual GBV cases with negative mental health outcomes
- Better care for sexual GBV cases
- Increased access to services for the prevention, care and management of sexual GBV in primary health care facilities and in communities
- Decrease in transmission of HIV due to sexual GBV
- Increase in number of convictions of perpetrators of sexual GBV

PROVISION OF STRATEGIC INFORMATION

The key expected outcomes are:

SHORT TERM:

- Increased number of data clerks with capacity to fulfill data management requirements
- Increased number of quality interventions implemented
- Increased number of pediatric and adult clients with electronic health records
- HIV prevalence trend reports available and disseminated

INTERMEDIATE:

- Improved recording and reporting systems in place
- HIV prevalence trend reports available and disseminated

LONG TERM:

- Functional continuous quality improvement system established
- Increased use of electronic health records to document continuity of care for pediatric and adult HIV/AIDS clients
- Increased monitoring of program impact on trends in HIV prevalence and causes of morbidity and mortality

iv. Funding Strategy

N/A

v. Strategies and Activities

The partner will be expected to carry out the following activities to contribute to towards achieving the listed objectives:

CARE AND TREATMENT OF HIV INFECTED PERSONS

The awardee will carry out the following activities:

- Provide comprehensive clinical management of HIV infected persons including screening

and treatment for TB, STIs and OIs and ART for treatment eligible persons

- Monitor the impact of ART on individuals through VL testing and HIV drug resistance testing for those with suspected treatment failure
- Provide nutritional counselling and food supplementation, as appropriate to HIV infected persons and their families
- Assist MOH to strengthen skills of clinicians and infrastructure of hospitals for improved quality of HIV case management

DETECTION, CARE AND SUPPORT OF HIV/TB CO-INFECTED PERSONS

The awardee will carry out the following activities:

- Provide reciprocal screening and treatment for HIV and TB in respective service delivery areas
- Provide TB prophylaxis or treatment for HIV infected persons
- Conduct TB Infection control activities to prevent nosocomial infections among patients and health care workers in pediatric and adult clinical wards and service areas

PREVENTION OF MOTHER TO CHILD TRANSMISSION OF HIV/AIDS

The awardee will carry out the following activities in Maternal, Neonatal and Child Health (MNCH) settings:

- Conduct HIV and STI screening for pregnant women and their sex partners
- Integrate services for HIV, Sexual Reproductive Health (SRH) and Family Planning (FP) in MNCH settings
- Establish surveillance for ARV toxicity in women and birth defects in infants who are exposed to Efavirenz (EFV) and Tenofovir (TDF) containing ART regimens
- Implement a mother-baby pair tracking system to document clinical outcomes after referral to named primary care facilities

DIAGNOSIS, CARE AND SUPPORT FOR INFANTS AFFECTED BY HIV/AIDS

The awardee will carry out the following activities:

- Provide services for diagnosis, treatment and clinical management of HIV exposed infants
- Provide specialized services for assessment of and assistance to HIV exposed infants to address nutritional and developmental needs

HIV TESTING AND COUNSELLING

The awardee will carry out the following activities:

- Institutionalize Provider Initiated Counselling and Testing for all children and adults who access hospital services
- Strengthen couples counselling and testing and provide follow up services

STRENGTHEN LABORATORY SERVICES

The awardee will carry out the following activities:

- Provide on-site capacity for testing key analytes
- Identify and resolve problems that lead to failure to provide laboratory results
- Provide proficiency test programs to document accuracy of laboratory testing
- Train laboratory personnel to carry out testing for key analytes

REDUCTION OF IMPACT OF SEXUAL GENDER BASED VIOLENCE (GBV)

The awardee will carry out the following activities:

- Provide information and support for Sexual GBV

- Engage stakeholders to increase the range of services that are made available to sexual GBV cases
- Scale up sexual GBV services through training of health care and integration of services down to community level health facilities
- Provide medical evaluation of sexual GBV cases and establish forensic investigative capacity to aid in conviction of perpetrators of GBV

PROVISION OF STRATEGIC INFORMATION

The awardee will carry out the following activities:

- Develop and implement a monitoring evaluation and reporting (MER) plan
- Expand use of electronic health records to improve patient management, service delivery and program MER

1. Collaborations:

The awardee will be required to work with the following program to achieve FOA outcomes: The Center for Global Health and AIDS through the CDC Country Office for technical assistance in implementation of all HIV/AIDS program areas.

The Awardee will be required to work with the following organizations external to CDC, but who receive financial support through CDC and PEPFAR for HIV/AIDS related activities:

- Ministry of Health, Ministry of Community Development Mother Child Health for human resources development, preparation of national guidelines and policies for clinical and laboratory services;
- Provincial health authorities in Eastern, Lusaka, Southern and Western Provinces for establishment of Advanced HIV treatment Centers, for referral of patients to provincial or district facilities for follow-up care and treatment, and for distribution and follow-up with HIV testing sites that participate in laboratory proficiency test programs.

2. Target Populations:

The selected Awardee will target all adults and children attending a tertiary referral hospital in Lusaka, Zambia, for clinical or treatment services as well as persons affected by Sexual Gender Based Violence.

Inclusion:

N/A

b. Evaluation and Performance Measurement:

i. CDC Evaluation and Performance Measurement Strategy:

Throughout the 5-year FOA period, DGHA/CDC Zambia will work with awardee to demonstrate program impact through process and outcome evaluation of funded activities. Process indicators will be used to assess the extent to which planned program activities have been implemented. Outcome indicators will be used to assess the achievement of planned programmatic outcomes which generally focus on public health impact.

CDC Zambia will carry out the following activities to provide on-going technical assistance (TA) to awardees for MER:

- Orient the awardee on CDC PEPFAR reporting requirements and formats. These will include, but will not be limited to semi-annual and annual program results reporting
- Provide awardee with the documentation of all the standard PEPFAR Monitoring, Evaluation and Reporting (MER) indicators
- Provide technical assistance to the awardee to develop a Monitoring and Evaluation plan to respond to key program evaluation questions (see below), identify data sources, means of verification, time frames for evaluations and types of evaluations to be conducted.
- Convene monthly meetings between the awardee and the CDC Zambia technical team to review reports and discuss achievements or challenges of the program. Prior to each meeting the Awardee will be requested fill in a standardized data collection tool, developed by CDC Zambia, to summarize data to be discussed.
- Conduct Data Quality Audits (DQAs) of data submitted by the awardee
- Conduct periodic Site Monitoring System (SMS) and Service Quality Assessment (SQA) visits to service delivery sites for which CDC personnel will be accompanied by representatives of the awardee. SMS and SQA visits will be used to verify reported data, observe operational practices, identify gaps and mentor the awardee's staff for program quality improvement
- Recommend that the awardee conducts supportive supervisory visits to service delivery points at least once every three (3) months (quarterly) to observe practices, identify gaps, and mentor personnel towards improving service delivery quality and patient outcomes.
- Request the awardee to conduct a mid-term program evaluation and submit a report to answer questions that have been identified in the program MER (see below). The awardee will use mid-term evaluation results as a guide for program improvement
- Request the awardee to conduct an end of program evaluation and submit reports to CDC Zambia for review and onward submission to OGAC, USG, GRZ and various other local stakeholders working in the health sector

| <u>Evaluation Question</u> | <u>Performance Measure</u> | <u>Data Source</u> | <u>Collection Method</u> | <u>Collection Frequency</u> | <u>Dissemination and Utilization</u> |
|---|--|---|--|-----------------------------|--|
| How many persons have been initiated and retained on ART and what evidence is there for virus suppression? | <p>Number of persons initiated on ART</p> <p>Proportion of ART treated persons with “undetectable” viral load at 12 months using currently available technologies</p> <p>Proportion of ART treated persons with suspected treatment failure with HIV DR test results available</p> <p>Proportion of ART treated persons retained on treatment for ≥ 12 months</p> <p>Target $\geq 1,000$ children and $\geq 3,000$ adults initiated on ART $\geq 90\%$ treated persons with documented viral suppression by end of year 3 and $\geq 95\%$ by end of project $\geq 90\%$ of those with suspected treatment failure have regimen changes based on HIV DR results by end of year 3 and $\geq 95\%$ by end of project $\geq 95\%$ retained on treatment by end of year 3 and $\geq 95\%$ sustained up to end of project</p> | <p>Electronic Health Records Database</p> <p>Patient charts</p> <p>Laboratory reports</p> | Review of patient data | Semi-annually | <p>Results will be discussed during the annual national ART update meeting</p> <p>Findings will be used to:</p> <p>Inform continuous quality improvement of ART programs</p> <p>Inform ART scale-up plans</p> <p>Evaluate efficacy of treatment regimens</p> <p>Report on program impact in sAPR and APR reports</p> |
| What proportion of HIV infected persons had interventions to prevent or cure TB? | <p>Proportion of HIV infected persons without active TB receiving Isoniazid prophylaxis</p> <p>Proportion of HIV/TB co-infected persons put on TB treatment</p> <p>Target $> 40\%$ receive isoniazid prophylaxis end of</p> | <p>Electronic Health Records</p> <p>Patient records</p> | Review of patient records and clinic registers | Quarterly | <p>Results will be reported in sAPR and APR, discussed during the annual national ART update and TB meetings</p> <p>Findings will be used to improve and scale up isoniazid prophylaxis and TB treatment programs</p> |

| <u>Evaluation Question</u> | <u>Performance Measure</u> | <u>Data Source</u> | <u>Collection Method</u> | <u>Collection Frequency</u> | <u>Dissemination and Utilization</u> |
|---|---|---|--|-----------------------------|--|
| | year 3 and > 90% by end of project 100% HIV/TB co-infected persons receive TB treatment by end of year 1 and performance sustained to end of project | | | | |
| To what extent has the PMTCT program and integration of STI services resulted in reduction of rates of HIV PMTCT and new syphilis infections among repeat ANC attendees? | Proportion of HIV positive infants testing HIV positive Proportion of new syphilis infections among repeat ANC attendees Target < 9% by end of year 3 and < 5% for PMTC by end of project ≥ 80% reduction in new syphilis infections by end of year 3 and ≥ 90% by end of project | PMTCT national registers ANC clinic reports Patient records | Review of PMTC and ANC registers and patient records | Semi-annually | Results will be reported in sAPR and APR and discussed during the annual national ART update meeting Findings will be used to: Inform further PMTCT program scale-up Improve PMTCT program quality Strengthen integration of STI services in MNCH settings |
| What proportion of HIV exposed infants had EID tests results available 12 months of age, and ART initiated, as appropriate? | Proportion of HIV exposed infants receiving EID tests by 12 months of age Proportion of HIV infected, treatment eligible infants initiated on ART by 12 months of age Target ≥ 95% of infants with EID results by end of year one and performance sustained to end of project > 95% of treatment eligible infants initiated on ART by 12 months of age | PMTCT registers | Review of patient records and clinic registers | Annually | Results will be discussed during the annual national ART update meeting Findings will be used to: Inform further EID program scale-up Improve EID program quality |
| What proportion of newly detected HIV infections are due to PICT | Proportion of all new HIV diagnoses attributable to PICT Proportion of newly diagnosed treatment eligible persons initiated on ART | Patient records, Clinic and ward registers, Patient records | Abstraction of data on site where HIV test was | Monthly | Results will be discussed during monthly meetings between Awardee and CDC Findings will be used to: |

| <u>Evaluation Question</u> | <u>Performance Measure</u> | <u>Data Source</u> | <u>Collection Method</u> | <u>Collection Frequency</u> | <u>Dissemination and Utilization</u> |
|--|--|--|--|-----------------------------|--|
| provided on-site and what evidence is there of linking newly diagnosed persons linked to treatment? | <p>Target ≥ 95% by end of year three and sustained to end of project ≥ 95% newly diagnosed treatment eligible persons initiated by end of year three and sustained to end of project</p> | | performed and patient referral information from reviewed records | | <p>Inform planning for training and allocation of personnel</p> <p>Improve PITC performance on-site</p> <p>Scale up PICT in other locations through training and mentorship</p> <p>Strengthen linkages of HIV persons to care and treatment services</p> |
| What evidence is there for the Awardee having trained persons who are competent to provide accurate high quality laboratory results for key analytes? | <p>Proportion of all national test sites that enroll and pass PTs coordinated by the partner</p> <p>Number of trained persons who pass post-workshop competency evaluations</p> <p>Number of awardees on site laboratory units accredited to international standard</p> <p>Target ≥ 95% enrolled in PT programs by end of year 2 and sustained to end of project; ≥ 95% enrolled sites passing PT by end of year 2 and sustained to end of project > 90% of trainee pass competency evaluations by end of year 3 and > 95% by end of project > 3 laboratory units accredited by end of year 3 and > 3 by end of project</p> | <p>PT program data</p> <p>Competency evaluation results for trainees</p> <p>Laboratory audit reports</p> | Review of reports and audit reports | Semi-annually | <p>Written PT reports to individual test sites and stakeholders PT reports included in sAPR and APR reporting</p> <p>Feedback on Competency evaluations to trainees</p> <p>Audit report discussions with host institute, MOH, CDC and other stakeholders</p> <p>Findings will be used: By PT providers and sites to take corrective action</p> <p>By PT stakeholders to advocate for resources for laboratories</p> <p>By MOH and CDC to strengthen accreditation related training and mentoring to address deficiencies</p> |

| <u>Evaluation Question</u> | <u>Performance Measure</u> | <u>Data Source</u> | <u>Collection Method</u> | <u>Collection Frequency</u> | <u>Dissemination and Utilization</u> |
|---|---|--|---|-----------------------------|---|
| | | | | | identified through laboratory audits |
| What proportion of sexual GBV cases complete HIV post-exposure PEP regimen, received psychosocial supportive services and have appropriate forensic evidence collected and analyzed to aid in legal convictions? | <p>Proportion of sexual GBV cases that receive HIV PEP within 72 hours of assault and complete regimen</p> <p>Proportion of sexual GBV cases that receive psychosocial supporting services</p> <p>Proportion of sexual GBV cases with forensic investigations performed</p> <p>Target Approximately 500 adults and 1000 children access GBV services annually > 90% of those receive and complete PEP (as appropriate) by end of year 2 and > 95% by end of project > 90% receive psychosocial support services end of year 2 and > 95% by end of project > 50% with forensic samples investigated (as appropriate) by end of year 2 and > 90% by end of project</p> | <p>Individual case records</p> <p>Multidisciplinary team meeting reports</p> <p>Forensic reports</p> | <p>Review of case records and reports</p> | <p>Quarterly</p> | <p>Quarterly meetings of multidisciplinary teams to review data</p> <p>Findings will be used to: Expedite investigative processes</p> <p>Improve linkages of GBV cases to HCT services</p> <p>Strengthen links to legal services</p> |
| Is there evidence that the Partner's programs are having an impact on reducing HIV morbidity and mortality? | <p>Availability of MER data to respond to the key evaluation questions (1 to 7 above)</p> <p>Target > 90% of program targets achieved by mid-term and > 95% by end of project</p> | <p>Program MER reports</p> | <p>SAPR and APR reports</p> | <p>Semi-annual</p> | <p>Semi-annual meetings between Awardee and CDC to review MER data</p> <p>Findings will be used to: Inform Program Quality</p> <p>Improvement efforts</p> <p>Report to stakeholders</p> |

ii. Applicant Evaluation and Performance Measurement Plan:

Applicants must provide an overall jurisdiction- or community-specific evaluation and performance measurement plan that is consistent with the CDC strategy. At a minimum, the plan must:

- Describe how key program partners will participate in the evaluation and performance measurement planning processes.
- Describe the type of evaluations (i.e., process, outcome, or both) to be conducted.
- Describe key evaluation questions. Describe other information (e.g., performance measures to be developed by the applicant), as determined by the CDC program, that must be included.
- Describe potentially available data sources and feasibility of collecting appropriate evaluation and performance data.
- Describe how evaluation findings will be used for continuous program quality improvement.
- Describe how evaluation and performance measurement will contribute to developing an evidence base for programs that employ strategies lacking a strong effectiveness evidence base.

c. Organizational Capacity of Awardees to Execute the Approach:

Applicant must be able to manage program performance, evaluation, performance monitoring, financial reporting, and must have capacity to manage the required funds in accordance with the HHS Grants Policy Statement, which can be found at:

<http://www.hhs.gov/asfr/ogapa/aboutog/hhsgps107.pdf>

d. Work Plan:

Applicant must include a work plan that demonstrates how the outcomes, strategies, activities, timelines, and staffing will take place over the course of the award. Applicants must submit a detailed work plan for the first year of the project and a high level plan for the subsequent years.

e. CDC Monitoring and Accountability Approach

Monitoring activities include routine and ongoing communication between CDC and awardees, site visits, and awardee reporting (including work plans, performance, and financial reporting). HHS grants policy specifies the following HHS expectations for post-award monitoring for grants and cooperative agreements:

- Tracking awardees progress in achieving the desired outcomes.
- Insuring the adequacy of awardee systems that underlie and generate data reports.
- Creating an environment that fosters integrity in program performance and results.

Monitoring may also include the following activities:

- Ensuring that work plans are feasible based on the budget and consistent with the intent of the award.
- Ensuring that awardees are performing at a sufficient level to achieve objectives within stated timelines.
- Working with awardees on adjusting the work plan based on achievement of objectives and changing budgets.
- Monitoring performance measures (both programmatic and financial) to assure satisfactory performance levels.
- Other activities deemed necessary to monitor the award, if applicable.

These may include monitoring and reporting activities as outlined in HHS grants policy that assists grants management staff (e.g., grants management officers and specialists, and project officers) in the identification, notification, and management of high-risk grantees.

f. CDC Program Support to Awardees

In a cooperative agreement, CDC staff is substantially involved in the program activities, above and beyond routine grant monitoring. CDC activities for this program are as follows:

1. Organize an orientation meeting with the grantee for a briefing on applicable U.S. Government, HHS/CDC, and President's Emergency Plan for AIDS Relief (PEPFAR) expectations, regulations and key management requirements, as well as report formats and contents. The orientation could include meetings with staff from HHS agencies and the Office of the U.S. Global AIDS Coordinator (OGAC).
2. Review and make recommendations as necessary to the process used by the grantee to select key personnel and/or post-award subcontractors and/or subgrantees to be involved in the activities performed under this agreement, as part of the President's Emergency Plan for Relief (PEPFAR) Country Operational Plan (COP) review and approval process, managed by the OGAC.
3. Review and approve grantee's annual work plan and detailed budget, as part of the Emergency Plan for AIDS Relief Country Operational Plan review-and-approval process, managed by the Office of the U.S. Global AIDS Coordinator.
4. Review and approve the grantee's monitoring and evaluation plan, including for compliance with the strategic information guidance established by the OGAC.
5. Meet on a regular basis with the grantee to assess expenditures in relation to approved work plan and modify plans as necessary.
6. Meet on a quarterly basis with the grantee to assess quarterly technical and financial progress reports and modify plans as necessary.
7. Meet on an annual basis with the grantee to review annual progress report for each U.S. Government Fiscal Year, and to review annual work plans and budgets for the subsequent year, as part of the PEPFAR review and approval process for COPs, managed by OGAC.
8. Provide technical assistance, as mutually agreed upon, and revise annually during validation of the first and subsequent annual work plans. This could include expert technical assistance and targeted training activities in specialized areas, such as strategic information, project management, and confidential counseling and testing.
9. Provide in-country administrative support to help the grantee meet U.S. Government financial and reporting requirements approved by the Office of Management and Budget (OMB) under 0920-0428.
10. Collaborate with the grantee on designing and implementing the activities listed above, including, but not limited to: the provision of technical assistance to develop program activities, data management and analysis, quality assurance, the presentation and possibly

publication of program results and findings, and the management and tracking of finances.

11. Provide technical assistance or advice on any data collections on 10 or more people that are planned or conducted by the awardee. All such data collections-- where CDC staff will be or are approving, directing, conducting, managing, or owning data-- must undergo OMB project determinations by CDC and may require OMB PRA clearance prior to the start of the project.
12. Provide consultation and scientific and technical assistance based on appropriate HHS/CDC and OGAC documents to promote the use of best practices known at the time.
13. Assist the grantee in developing and implementing quality-assurance criteria and procedures.
14. Facilitate in-country planning and review meetings for technical assistance activities.
15. Provide technical oversight for all activities under this award.
16. Conduct service delivery site visits through the Site Monitoring System (SMS) to monitor and evaluate site capacity to provide high-quality HIV/AIDS services in all program areas by assessing and scoring key program area elements of site performance and work with the grantee on identified gaps and continuous quality improvement.
17. Provide ethical reviews, as necessary, for evaluation activities, including from HHS/CDC headquarters. Evaluations can be process, outcome or impact.
 - A. Process Evaluation: measures how the intervention was delivered, what worked/did not, differences between the intended population and the population served, and access to the intervention.
 - B. Outcome Evaluation: determines effects of intervention in target population(s) (e.g., change in knowledge, attitudes, behavior, capacity, etc.).
 - C. Impact Evaluation: measures net effects of program and prove of causality
18. Supply the awardee with protocols for related evaluations.
19. CDC Staff are embedded in the University Teaching Hospital, Pediatric Centre of Excellence and work to build capacity.
20. CDC Technical staff provide laboratory, clinical, data management and other technical assistance at the University Teaching Hospital and assist in teaching.
21. Work with the grantee to develop and implement a realistic, phased sustainability plan which progressively increases the financial, managerial and technical investment of the Government of Zambia and Recipient Organization to respond to the national HIV epidemic; as well as progress towards the sustainability of activities. Activities will include an assessment and the development of a sustainability plan to build institutional capacity in the areas of systems strengthening, policy, and organizational and human resource requirements.

| B. Award Information | |
|---|--|
| 1. Type of Award: | Cooperative Agreement: CDC's substantial involvement in this program is indicated in the "CDC program Support to Awardees" section of this document. |
| 2. Award Mechanism: | U2G-Global HIV/AIDS Non-Research Cooperative Agreements |
| 3. Fiscal Year: | 2015 |
| 4. Approximate Total Fiscal Year Funding: | \$5,495,000.00 |
| 5. Approximate Total Project Period Funding: | None |
| 6. Total Project Period Length: | 5 Years |
| 7. Approximate Number of Awards: | 1 |
| 8. Approximate Average Award: | \$5,495,000.00 |
| 9. Floor of Individual Award Range: | None |
| 10. Ceiling of Individual Award Range: | \$5,495,000.00 (This amount is subject to the availability of funds). |
| 11. Anticipated Award Date: | April 1, 2015 |
| 12. Budget Period Length: | 12 months Throughout the project period, CDC will continue the award based on the availability of funds, the evidence of satisfactory progress by the awardee (as documented in required reports), and the determination that continued funding is in the best interest of the federal government. The total number of years for which federal support has been approved (project period) will be shown in the "Notice of Award." This information does not constitute a commitment by the federal government to fund the entire period. The total project period comprises the initial competitive segment and any subsequent non-competitive continuation award(s). <i>Note: Applicants must only apply for the first budget period funding, taking into consideration the floor of the individual award range and the ceiling of the individual award range. The proposed budget for the first budget period must not exceed the ceiling of the individual award range. If a funding amount greater than the ceiling of the individual award range is requested, the application will be considered non-responsive and will not be entered into the review process.</i> |
| 13. Funds Tracking: | Applicant is required to track fund by P-accounts/sub accounts for each project/cooperative agreement |

| |
|--|
| awarded. |
| 14. Direct Assistance: |
| Direct assistance is not available through this FOA |
| 15. Indirect Costs: |
| Indirect costs will not be reimbursed under grants to foreign organizations, international organizations, and foreign components of grants to domestic organizations (does not affect indirect cost reimbursement to the domestic entity for domestic activities). The CDC will not reimburse indirect costs unless the recipient has an indirect cost rate covering the applicable activities and period. |
| C. Eligibility Information |
| 1. Eligible Applicants: |
| Eligible applicants that can apply for this FOA are listed below: The University Teaching Hospital (UTH) |
| 2. Special Eligibility Requirements: |
| N/A |
| 3. Justification for Less than Maximum Competition: |
| <p>This funding opportunity announcement is proposed to be single sourced to the University Teaching Hospital (UTH), located in Lusaka Province of the Republic of Zambia. UTH is the national tertiary reference hospital in the capital city, Lusaka, with a government mandate to provide in- and out- patient services to the entire country, although the majority of patients are from Lusaka province. UTH has a 1,863 bed capacity and has developed Pediatric and Adult Centers of Excellence for the care and treatment of HIV/AIDS patients. UTH is also the main medical and paramedical teaching and resource center in the country, and is the host institute for several national reference laboratories. Additionally the hospital hosts all the major specialist clinics and has community outreach programs that support out of hospital care for patients.</p> <p>In 2003, UTH worked in cooperation with CDC to provide counseling and testing services for high risk Sexually Transmitted Infections (STIs) patients and this also resulted in the upgrading of the STI laboratory. In subsequent years, UTH received funding from CDC to support larger pediatric and adult care and treatment programs. These included support for unique activities like the one stop child sexual abuse programs, community based nutrition program, children's developmental intervention clinic and national external quality assurance programs for the laboratories.</p> <p>The new project will strengthen prior and ongoing CDC supported activities in the areas of counseling and testing, HIV prevention and treatment and laboratory infrastructure development. The new project will also focus on integration of services, dealing with complicated cases, drug resistance testing and third line treatment, transitioning of human resource from project staff to MOH staff and support towards the establishment of first ever forensic science laboratory in Zambia.</p> <p>Justification for single eligibility memo approved on September 8, 2014.</p> |
| 4. Other: |
| N/A |
| 5. Cost Sharing or Matching: |
| Cost sharing or matching funds are not required for this program. Although there is no statutory match requirement for this FOA, leveraging other resources and related ongoing efforts to promote |

sustainability is strongly encouraged.

6. Maintenance of Effort:

Maintenance of Effort is not required for this program.

D. Application and Submission Information

Additional materials that may be helpful to applicants:

<http://www.cdc.gov/od/pgo/funding/docs/FinancialReferenceGuide.pdf>.

1. Required Registrations:

An organization must be registered at the three following locations before it can submit an application for funding at www.grants.gov.

- a. **Data Universal Numbering System:** All applicant organizations must obtain a Data Universal Numbering System (DUNS) number. A DUNS number is a unique nine-digit identification number provided by Dun & Bradstreet (D&B). It will be used as the Universal Identifier when applying for federal awards or cooperative agreements.

The applicant organization may request a DUNS number by telephone at 1-866-705-5711 (toll free) or internet at <http://fedgov.dnb.com/webform/displayHomePage.do>. The DUNS number will be provided at no charge.

If funds are awarded to an applicant organization that includes sub-awardees, those sub-awardees must provide their DUNS numbers before accepting any funds.

- b. **System for Award Management (SAM):** The SAM is the primary registrant database for the federal government and the repository into which an entity must submit information required to conduct business as an awardee. All applicant organizations must register with SAM, and will be assigned a SAM number. All information relevant to the SAM number must be current at all times during which the applicant has an application under consideration for funding by CDC. If an award is made, the SAM information must be maintained until a final financial report is submitted or the final payment is received, whichever is later. The SAM registration process can require 10 or more business days, and registration must be renewed annually. Additional information about registration procedures may be found at www.SAM.gov.
- c. **Grants.gov:** The first step in submitting an application online is registering your organization at www.grants.gov, the official HHS E-grant Web site. Registration information is located at the "Get Registered" option at www.grants.gov.

All applicant organizations must register at www.grants.gov. The one-time registration process usually takes not more than five days to complete. Applicants should start the registration process as early as possible.

| Step | System | Requirements | Duration | Follow Up |
|------|-------------------------------------|---|-------------------|---|
| 1 | Data Universal Number System (DUNS) | 1. Click on http://fedgov.dnb.com/webform 2. Select Begin DUNS search/request process 3. Select your country or territory and follow the instruction to obtain your DUNS 9-digit # 4. Request appropriate staff member(s) to obtain DUNS number, verify & update information under DUNS number | 1-2 Business Days | To confirm that you have been issued a new DUNS number check online at http://fedgov.dnb.com/webform or call 1-866-705-5711 |
| 2 | System for Award | 1. Retrieve organizations DUNS number | 3-5 Business Days | For SAM Customer Service Contact |

| | | | | |
|---|---|---|--|--|
| | Management (SAM) formerly Central Contractor Registration (CCR) | 2. Go to www.sam.gov and designate an E-Biz POC (note CCR username will not work in SAM and you will need to have an active SAM account before you can register on grants.gov) | but up to 2 weeks and must be renewed once a year | www.fsd.gov/US Calls: 866-606-8220 |
| 3 | Grants.gov | <ol style="list-style-type: none"> 1. Set up an individual account in Grants.gov using organization new DUNS number to become an authorized organization representative (AOR) 2. Once the account is set up the E-BIZ POC will be notified via email 3. Log into grants.gov using the password the E-BIZ POC received and create new password 4. This authorizes the AOR to submit applications on behalf of the organization | Same day but can take 8 weeks to be fully registered and approved in the system (note, applicants MUST obtain a DUNS number and SAM account before applying on grants.gov) | Register early! Log into grants.gov and check AOR status until it shows you have been approved |

2. Request Application Package:

Download the application package from www.grants.gov

3. Application Package

Applicants must download the SF-424 application package associated with this funding opportunity from www.grants.gov. If Internet access is not available, or if the online forms cannot be accessed, applicants may call the CDC PGO staff at 770-488-2700 or e-mail PGO PGOTIM@cdc.gov for assistance. Persons with hearing loss may access CDC telecommunications at TTY 1-888-32-6348.

4. Submission Dates and Times:

If the application is not submitted by the deadline published in the FOA, it will not be processed. PGO personnel will notify the applicant that their application did not meet the deadline. The applicant must receive pre-approval to submit a paper application (see Other Submission Requirements section for additional details). If the applicant is authorized to submit a paper application, it must be received by the deadline provided by PGO.

If Grants.gov cannot receive applications due to an emergency or other unanticipated event (and circumstances preclude advance notification of an extension), then applications must be submitted by the first business day on which government operations resume.

a. Letter of Intent (LOI) Deadline Date: (must be postmarked by): N/A

b. Application Deadline Date: January 23, 2015, 11:59 p.m. U.S. Eastern Standard Time, at www.grants.gov. Late submissions will be considered non-responsive.

If Grants.gov cannot receive applications due to an emergency or other unanticipated event (and circumstances preclude advance notification of an extension), then applications must be submitted by the first business day on which government operations resume.

5. CDC Assurances and Certifications:

All applicants are required to sign and submit CDC Assurances and Certifications documents that can be found on the CDC Web site: <http://www.cdc.gov/od/pgo/funding/grants/foamain.shtm>

Applicants may follow either of the following processes:

- Applicants must name this file "Assurances and Certifications" and upload as a PDF on www.grants.gov.
- Complete the applicable assurances and certifications and submit them directly to CDC on an annual basis at <http://www.cdc.gov/od/pgo/funding/grants/foamain.shtm>

Assurances and certifications submitted directly to CDC will be kept on file for 1 year and will apply to all

| |
|--|
| applications submitted to CDC within one year of the submission date. |
| 6. Content and Form of Application Submission: |
| Applicants are required to submit all of the documents outlined below as their application package on www.grants.gov . |
| 7. Letter of Intent (LOI): |
| A letter of intent is not applicable to this funding opportunity announcement. |
| 8. Table of Contents: |
| Provide a detailed table of contents for the entire submission package that includes all of the documents in the application and headings in the “Project Narrative” section. Name the file “Table of Contents” and upload it as a PDF file under “Other Attachment Forms” at www.grants.gov . There is no page limit. The table of contents is not included in the project narrative page limit |
| 9. Project Abstract Summary: |
| (Maximum of 1 page) A project abstract is included on the mandatory documents list and must be submitted at www.grants.gov . The project abstract must be a self-contained, brief summary of the proposed project including the purpose and outcomes. This summary must not include any proprietary or confidential information. Applicants must enter the summary in the “Project Abstract Summary” text box at www.grants.gov . |
| 10. Project Narrative: |
| (Maximum of 18 pages, single spaced, Calibri 12 point, 1-inch margins, number all pages, content beyond 18 pages will not be reviewed). The Project Narrative must include all of the bolded headings shown in this section. The Project Narrative must be succinct, self-explanatory, and in the order outlined in this section. It must address outcomes and activities to be conducted over the entire project period as identified in the CDC Project Description section. Applicants must submit a Project Narrative with the application forms. Applicants must name this file “Project Narrative” and upload it at www.grants.gov . a. Background: Applicants should provide a description of relevant background information that includes the context of the problem (see CDC Background). b. Approach Problem Statement: Applicants must describe the core information relative to the problem for the jurisdictions or populations they serve. The core information should help reviewers understand how the applicant’s response to the FOA will address the public health problem and support public health priorities. (See CDC Project Description). Purpose: Applicants must describe specifically how their application will address the problem as described in the CDC Project Description. Outcomes: Applicants must clearly identify the outcomes they expect to achieve by the end of the project period. Outcomes are the results that the program intends to achieve. All outcomes should indicate the intended direction of change (i.e., increase, decrease, maintain). See the program logic model in the Approach section of the CDC Project Description. In addition to the project period outcomes required by CDC, applicants should include any additional outcomes they anticipate. |

Strategy and Activities: The applicant must provide a clear and concise description of the strategies and activities they will use to achieve the project period outcomes. Whenever possible, applicants should use evidence-based program strategies as identified by the Community Guide¹ (or similar reviews) and reference it explicitly as a source. Applicants may propose additional strategies and activities to achieve the outcomes. Applicants should select existing evidence-based strategies that meet their needs, or describe the rationale for developing and evaluating new strategies or practice-based innovations. (See CDC Project description: Strategies and Activities section).

1. **Collaborations:** Applicants must describe how they will collaborate with CDC funded programs as well as with organizations external of CDC.

Applicants responding to this FOA will be required to provide evidence (e.g. MOAs, MOUs, LOIs) of prior collaboration with CDC funded programs or organizations external to CDC that receive CDC or PEPFAR funding. Applicants must provide MOUs/MOAs/LOIs and name the file "MOUs/MOAs/LOIs" and upload as PDF files at www.grants.gov.

2. **Target Populations:** Applicants must describe the specific target population(s) to be addressed in their jurisdiction to allocate limited resources, target those at greatest health risk, and achieve the greatest health impact. Applicants should use data, including social determinants data, to identify communities within their jurisdictions or community served that are disproportionately affected by the public health problem, and plan activities to reduce or eliminate these disparities. Disparities by race, ethnicity, gender identity, sexual orientation, geography, socioeconomic status, disability status, primary language, health literacy, and other relevant dimensions (e.g., tribal communities) should be considered.

Inclusion: N/A

- c. **Applicant Evaluation and Performance Measurement Plan:** Applicants must provide an overall jurisdiction or community-specific evaluation and performance measurement plan that is consistent with the CDC Evaluation and Performance Measurement Strategy section of the CDC Project Description of this FOA. Data collected must be used for ongoing monitoring of the award to evaluate its effectiveness, and for continuous program improvement.

The plan must:

- Describe how key program partners will be engaged in the evaluation and performance measurement planning processes.
- Describe the type of evaluations to be conducted (i.e. process and/or outcome).
- Describe key evaluation questions to be answered.
- Describe other information, as determined by the CDC program (e.g., performance measures to be developed by the applicant) that must be included.
- Describe potentially available data sources and feasibility of collecting appropriate evaluation and performance data.
- Describe how evaluation findings will be used for continuous program and quality improvement.

¹ <http://www.thecommunityguide.org/index.html>

- Describe how evaluation and performance measurement will contribute to development of that evidence base, where program strategies are being employed that lack a strong evidence base of effectiveness.

Awardees will be required to submit a more detailed evaluation and performance measurement plan within the first six months of the project, as outlined in the reporting section of the FOA.

d. Organizational Capacity of Awardees to Execute the Approach:

Applicant must address the organizational capacity requirements as described in the CDC Project Description. Applicants must submit CVs/Resumes of the Principal Investigator and Business Official as well as detailed job descriptions of proposed key positions to be created for Cooperative Agreement (CoAg) Coordinator, CoAg finance specialist, CoAg Monitoring and Evaluation and Specialist necessary for program development and implementation. Applicants must also submit Organizational Charts. These items must be submitted as part of the appendix, clearly named "CVs/Resumes," "Job Descriptions," and "Organizational Charts," and uploaded as PDF files at www.grants.gov.

11. Work Plan:

(Included in the Project Narrative- 18 page limit)

Applicants must prepare a work plan consistent with the CDC Project Description Work Plan section. The work plan integrates and delineates more specifically how the awardee plans to carry out achieving the project period outcomes, strategies, and activities, evaluation and performance measurement, including key milestones.

12. Budget Narrative:

Applicants must submit an itemized, line-item budget and narrative with staffing breakdown (i.e., name, position title, annual salary, percentage of time and effort, and amount requested) and justification for all requested costs for the first budget period. Budgets must be consistent with the purpose, objectives of the Emergency Plan, and the program activities listed in this announcement. When developing the budget narrative, applicants should consider whether the proposed budget is reasonable and consistent with the purpose, outcomes and program strategy outlined in the project narrative. The budget must include:

- Salaries and wages
- Fringe benefits
- Consultant costs
- Equipment
- Supplies
- Travel
- Alterations and Renovations
- Other categories
- Contractual costs
- Total Direct costs
- Total Indirect costs

The detailed budget should identify costs associated with potential data collection activities from persons, personal records, or for laboratory specimen collection and testing that may result in a public report. For each of the potential data collection activities, also state the costs for any preparatory activities (e.g., protocol development, training, equipment, reagents, and site preparation).

When developing the budget narrative, applicants should consider whether the proposed budget is

reasonable and consistent with the purpose, outcomes and program strategy outlined in the project narrative. All budget justification pages must be numbered.

For guidance on completing a detailed budget, see Budget Preparation Guidelines at: <http://www.cdc.gov/od/pgo/funding/budgetguide.htm>.

Applicants should name this “Budget Narrative” and upload as a PDF file to www.grants.gov.

If requesting indirect costs in the budget, a copy of the indirect cost rate agreement is required. If the indirect cost rate is a provisional rate, the agreement must have been made less than 12 months earlier. Applicants should name this file “Indirect Cost Rate” and upload to www.grants.gov.

If a funding amount greater than the ceiling of the individual award range is requested, the application will be considered non-responsive and will not be entered into the review process. The applicant will be notified that the application did not meet the eligibility requirements.

13. Tobacco and Nutrition Policies:

Awardees are encouraged to implement tobacco and nutrition policies.

Unless otherwise explicitly permitted under the terms of a specific CDC award, no funds associated with this FOA can be used to implement the optional policies, and no applicants will be evaluated or scored on whether they choose to participate in implementing these optional policies.

The CDC supports implementing evidence-based programs and policies to reduce tobacco use and secondhand smoke exposure, and to promote healthy nutrition. CDC encourages all awardees to implement the following optional recommended evidence-based tobacco and nutrition policies within their own organizations. This builds upon the current federal commitment to reduce exposure to secondhand smoke, which includes The Pro-Children Act, 20 U.S.C. 7181-7184, that prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, or early childhood development services are provided to children.

Tobacco Policies:

1. Tobacco-free indoors – no use of any tobacco products (including smokeless tobacco) or electronic cigarettes in any indoor facilities under the control of the awardee
2. Tobacco-free indoors and in adjacent outdoor areas – no use of any tobacco products or electronic cigarettes in any indoor facilities, within 50 feet of doorways and air intake ducts, and in courtyards under the control of the awardee
3. Tobacco-free campus – no use of any tobacco products or electronic cigarettes in any indoor facilities and anywhere on grounds or in outdoor space under the control of the awardee

Nutrition Policies:

1. Healthy food service guidelines should at a minimum, align with Health and Human Services and General Services Administration Health and Sustainability Guidelines for Federal Concessions and Vending Operations for cafeterias, snack bars, and vending machines in any facility under the control of the awardee and in accordance with contractual obligations for these services (http://www.gsa.gov/graphics/pbs/Guidelines_for_Federal_Concessions_and_Vending_Operations.pdf)
2. The following are resources for healthy eating and tobacco free workplaces:
<http://www.cdc.gov/nccdphp/dnpao/hwi/toolkits/tobacco/index.htm>
<http://www.thecommunityguide.org/tobacco/index.html>

14. Intergovernmental Review:

Executive Order 12372 does not apply to this program.

15. Funding Restrictions:

Restrictions that must be considered while planning the programs and writing the budget are:

- Awardees may not use funds for research.
- Awardees may not use funds for clinical care except as allowed by law.
- Awardees may only use funds for reasonable program purposes, including personnel, travel, supplies, and services (such as contractual).
- Generally, awardees may not use HHS/CDC/ATSDR funding for the purchase of furniture or equipment. Any such proposed spending must be clearly identified in the budget in accordance with CDC's budget guidelines.
- Pre-award costs may be allowable for successful applicants under this FOA prior to award.
- Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC awardees.
- The direct and primary recipient in a cooperative agreement program must perform a substantial role in carrying out project outcomes and not merely serve as a conduit for an award to another party or provider who is ineligible.
- The applicant may contract with other organizations under this program; however the applicant must perform a substantial portion of the activities (including program management and operations, and delivery of prevention services for which funds are required.)
- All plans for data collection from persons or personal records and for laboratory specimen collection and testing that are expected to result in public reports will require protocols for technical review and review of institutional human subjects protection considerations by CDC. Funds for implementing these activities will be restricted until all necessary institutional protocol approvals have been obtained. Funds for preparatory activities (e.g., protocol development, training, equipment, reagents, and site preparation) may be provided prior to protocol approval. To facilitate the early availability of funding, the budget and narrative should clarify which activities are preparatory.
- Human subjects data collection funding restrictions which require submission of protocols will be submitted within six months of notification of such requirement, but no later than the end of the first budget year. Requests for exceptions to these deadlines will need to be submitted in writing to the Grants Management Officer. All protocol approvals should be obtained no later than the end of the second budget period after the award or Continuation has been made, provided that the Grantee submits their protocol no later than the deadline.
- Needle Exchange – No funds made available under this award may be used for needle exchange programs.
- The recipient must use funds provided under the agreement for costs incurred in carrying out the purposes of the award which are reasonable, allocable, and allowable in accordance with applicable cost principles. Unallowable costs will be determined in accordance with the applicable

cost principles.

- “Reasonable” means the costs do not exceed those that would ordinarily be incurred by a prudent person in the conduct of normal business.
- “Allocable” means the costs are necessary to the award.
- “Allowable” means the costs are reasonable and allocable, and conform to any limitations set forth in the award.
- The recipient is encouraged to obtain the Grants Management Officer’s written determination in advance whenever the recipient is uncertain as to whether a cost will be allowable.
- The costs that are generally allowable in grants to domestic organizations are allowable to foreign institutions and international organizations, with the following exception: With the exception of the American University, Beirut and the World Health Organization, Indirect Costs will not be paid (either directly or through sub-award) to organizations located outside the territorial limits of the United States or to international organizations regardless of their location.
- All requests for funds contained in the budget, shall be stated in U.S. dollars. Once an award is made, CDC will not compensate foreign grantees for currency exchange fluctuations through the issuance of supplemental awards.
- Public Financial Management Assessment Clause: The Parties acknowledge that HHS/CDC has assessed the recipient’s systems required to manage the activities supported with US Government funds under this Agreement and that this Agreement is expressly conditioned upon that assessment, as well as any measures, mitigation or means by which the recipient has or will address the vulnerabilities or weaknesses, if any, found in that assessment. The recipient agrees to take the necessary action(s) to address the recommendations or requirements of the assessment as agreed separately in writing with HHS/CDC in accordance with an action plan to be jointly developed to address such recommendations or as otherwise contained in this agreement.
- It is the policy of HHS/CDC to seek to ensure that none of its funds are used, directly or indirectly, to provide support to individuals or entities designated for United Nations Security Council sanctions. In accordance with this policy, the applicant agrees to use reasonable efforts to ensure that none of the funds provided under this grant are used to provide support of individuals or entities designated for UN Security Council sanctions (compendium of Security Council Targeted Sanctions Lists at: http://www.un.org/sc/committees/list_compend.shtml). This provision must be included in all sub-agreements, including contracts and sub-awards, issued under this award.
- **Prohibition on Assistance to Drug Traffickers**
 - HHS/CDC reserves the right to terminate assistance to, or take other appropriate measures with respect to, any participant approved by HHS/CDC who is found to have been convicted of a narcotics offense or to have been engaged in drug trafficking as defined in 22 CFR Part 140.
 - The Applicant agrees not to disburse, or sign documents committing the Applicant to disburse funds to a sub-recipient designated by HHS/CDC ("Designated Sub-recipient") until advised by HHS/CDC that: (1) any United States Government review of the Designated Sub-recipient and its key individuals has been completed; (2) any related certifications have been obtained; and (3) the assistance to the Designated Sub-recipient has been approved.
 - The Applicant shall insert the following clause, or its substance, in its agreement with the Designated Sub-recipient:
 - The Applicant reserves the right to terminate this Agreement or take other appropriate measures if the [Sub-recipient] or a key individual of the [Sub-recipient] is found to have been convicted of a narcotic offense or to have been engaged in drug trafficking as defined in 22 CFR Part 140.
- **Conference Costs and Fees**

U.S. Government funds under this award must not be used to finance the travel, per diem, hotel expenses, meals, conference fees or other conference costs for any member of a foreign government's delegation to an international conference sponsored by a multilateral organization, as defined below, unless approved by the CDC in writing.

- **Definitions:**
 - A foreign government delegation is appointed by the national government (including ministries and agencies but excluding local, state and provincial entities) to act on behalf of the appointing authority at the international conference. A conference participant is a delegate for the purposes of this provision, only when there is an appointment or designation that the individual is authorized to officially represent the government or agency. A delegate may be a private citizen.
 - An international conference is a meeting where there is an agenda, an organizational structure, and delegations from countries other than the conference location, in which country delegations participate through discussion, votes, etc.
 - A multilateral organization is an organization established by international agreement and whose governing body is composed principally of foreign governments or other multilateral organizations.
- **Using PEPFAR funds for Implementing Partners (IPs) and Partner Government Officials**

IPs are required to notify their Project Officer immediately upon abstract acceptance. Once accepted, IPs are required to submit a written justification to their Project Officer stating the rationale for seeking support to attend the conference. IPs with accepted oral posters or oral abstracts for presentations that give clear attribution to PEPFAR may be authorized to use PEPFAR funds for travel providing that funds are available for travel. Funds for travel must be drawn from an existing agreement with the IP and not from PEPFAR country program management and operations budget. IPs must obtain prior approval from their respective Project Officer for participation and on availability and use of funds.

PEPFAR partner government officials who wish to attend any large conference using PEPFAR funds must submit requests to the Project Officer, who will work with this PEPFAR Coordination office in-country, or to the designated PEPFAR Point of Contact in countries without Coordinators. Final decisions will be made in collaboration with the PEPFAR Deputy Principals and responses will be circulated to Post.

- **Attribution to PEPFAR**
 - All PEPFAR-related accepted abstracts presented by implementing partners during any conference (regardless of conference/meeting size) must be attributed to PEPFAR. All posters must include the PEPFAR logo as well as the following language: "This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through HHS/CDC under the terms of CDC-RFA-GH15-1603."
- **Abortion and Involuntary Sterilization Restrictions**
 - Funds made available under this award must not be used to pay for the performance of involuntary sterilization as a method of family planning or to coerce or provide any financial incentive to any individual to practice sterilization.
 - Prohibition on Abortion-Related Activities:
 - No funds made available under this award will be used to finance, support, or be attributed to the following activities: (i) procurement or distribution of equipment intended to be used for the purpose of inducing abortions as a method of family planning; (ii) special fees or incentives to any person to coerce or motivate them to have abortions; (iii) payments to persons to perform abortions or to solicit persons to undergo abortions; (iv) information, education, training, or communication

programs that seek to promote abortion as a method of family planning; and (v) lobbying for or against abortion. The term “motivate”, as it relates to family planning assistance, must not be construed to prohibit the provision, consistent with local law, of information or counseling about all pregnancy options.

- No funds made available under this award will be used to pay for any biomedical research which relates, in whole or in part, to methods of, or the performance of, abortions or involuntary sterilizations as a means of family planning. Epidemiologic or descriptive research to assess the incidence, extent or consequences of abortions is not precluded
- **Prostitution and Sex Trafficking**
 - A standard term and condition of award will be included in the final notice of award; all applicants will be subject to a term and condition that none of the funds made available under this award may be used to promote or advocate the legalization or practice of prostitution or sex trafficking. In addition, non-U.S. nongovernmental organizations will also be subject to an additional term and condition requiring the organization’s opposition to the practices of prostitution and sex trafficking.
- **Trafficking in Persons Provision**
 - No contractor or subrecipient under this Agreement that is a private entity may, during the period of time that the award is in effect:
 - engage in trafficking in persons, as defined in the Protocol to Prevent, Suppress, and Punish Trafficking in Persons, especially Women and Children, supplementing the UN Convention against Transnational Organized Crime;
 - procure any sex act on account of which anything of value is given to or received by any person; or
 - use forced labor in the performance of this award.
 - If HHS/CDC determines that there is a reasonable basis to believe that any private party contractor or subrecipient has violated paragraph 1 of this section or that an employee of the contractor or subrecipient has violated such a prohibition where that the employee’s conduct is associated with the performance of this award or may be imputed to the contractor or subrecipient, HHS/CDC may, without penalty, (i) require the Grantee to terminate immediately the contract or subaward in question or (ii) unilaterally terminate this Agreement in accordance with the termination provision.
 - For purposes of this provision, “employee” means an individual who is engaged in the performance in any part of the Project as a direct employee, consultant, or volunteer of any private party contractor or subrecipient.
 - The Applicant must include in all subagreements, including subawards and contracts, a provision prohibiting the conduct described in subsection a by private party subrecipients, contractors, or any of their employees
- **Requirements for Voluntary Family Planning Projects**
 - A family planning project must comply with the requirements of this paragraph.
 - A project is a discrete activity through which a governmental or nongovernmental organization or Public International Organization (PIO) provides family planning services to people and for which funds obligated under this award, or goods or services financed with such funds, are provided under this award, except funds solely for the participation of personnel in short-term, widely attended training conferences or programs.
 - (3) Service providers and referral agents in the project must not implement or be subject to quotas or other numerical targets of total number of births, number of family planning acceptors, or acceptors of a particular method of family planning. Quantitative estimates or indicators of the number of births, acceptors, and acceptors of a particular method that

are used for the purpose of budgeting, planning, or reporting with respect to the project are not quotas or targets under this paragraph, unless service providers or referral agents in the project are required to achieve the estimates or indicators.

- (4) The project must not include the payment of incentives, bribes, gratuities or financial rewards to (i) any individual in exchange for becoming a family planning acceptor, or (ii) any personnel performing functions under the project for achieving a numerical quota or target of total number of births, number of family planning acceptors, or acceptors of a particular method of contraception. This restriction applies to salaries or payments paid or made to personnel performing functions under the project if the amount of the salary or payment increases or decreases based on a predetermined number of births, number of family planning acceptors, or number of acceptors of a particular method of contraception that the personnel affect or achieve.
- (5) A person must not be denied any right or benefit, including the right of access to participate in any program of general welfare or health care, based on the person's decision not to accept family planning services offered by the project.
- The project must provide family planning acceptors comprehensible information about the health benefits and risks of the method chosen, including those conditions that might render the use of the method inadvisable and those adverse side effects known to be consequent to the use of the method. This requirement may be satisfied by providing information in accordance with the medical practices and standards and health conditions in the country where the project is conducted through counseling, brochures, posters, or package inserts.
 - The recipient must notify CDC when it learns about an alleged violation in the requirements for voluntary family planning projects described in paragraphs (3), (4), or (5), above.
 - The recipient must investigate and take appropriate corrective action, if necessary, when it learns about an alleged violation and must notify CDC about violations in a project affecting a number of people over a period of time that indicate there is a systemic problem in the project.
 - The recipient must provide CDC such additional information about violations as CDC may request.
- **Investment Promotion**
 - No funds or other support provided hereunder may be used to provide a financial incentive to a business enterprise currently located in the United States for the purpose of inducing such an enterprise to relocate outside the United States if such incentive or inducement is likely to reduce the number of employees of such business enterprise in the United States because United States production is being replaced by such enterprise outside the United States.
 - In the event the Applicant requires clarification from HHS/CDC as to whether the activity would be consistent with the limitation set forth above, the Applicant must notify HHS/CDC and provide a detailed description of the proposed activity. The Applicant must not proceed with the activity until advised by HHS/CDC that it may do so.
 - The Applicant must ensure that its employees and subcontractors and sub-recipients providing investment promotion services hereunder are made aware of the restrictions set forth in this clause and must include this clause in all subcontracts and other sub-agreements entered into hereunder.
- **Worker's Rights**
 - No funds or other support provided hereunder may be used for any activity that contributes to the violation of internationally recognized workers' rights of workers in the

recipient country.

- In the event the Applicant is requested or wishes to provide assistance in areas that involve workers' rights or the Applicant requires clarification from HHS/CDC as to whether the activity would be consistent with the limitation set forth above, the Applicant must notify HHS/CDC and provide a detailed description of the proposed activity. The Applicant must not proceed with the activity until advised by HHS/CDC that it may do so.
- The Applicant must ensure that all employees and subcontractors and sub-recipients providing employment-related services hereunder are made aware of the restrictions set forth in this clause and must include this clause in all subcontracts and other sub-agreements entered into hereunder.
- The term "internationally recognized worker rights" includes-- the right of association; the right to organize and bargain collectively; a prohibition on the use of any form of forced or compulsory labor; a minimum age for the employment of children, and a prohibition on the worst forms of child labor; and acceptable conditions of work with respect to minimum wages, hours of work, and occupational safety and health.
- The term "worst forms of child labor" means-- all forms of slavery or practices similar to slavery, such as the sale or trafficking of children, debt bondage and serfdom, or forced or compulsory labor, including forced or compulsory recruitment of children for use in armed conflict; the use, procuring, or offering of a child for prostitution, for the production of pornography or for pornographic purposes; the use, procuring, or offering of a child for illicit activities in particular for the production and trafficking of drugs; and work which, by its nature or the circumstances in which it is carried out, is likely to harm the health, safety, or morals of children, as determined by the laws, regulations, or competent authority of the country.
- **Contract Insurance Requirement**

To the extent that a host government partner enters into contracts expressly approved by the U.S. government, the host country government partner shall ensure that its contractors or subcontractors (a) provide, before commencing performance under any contracts or subcontracts funded under this agreement, such workers' compensation insurance or security as required by HHS/CDC and (b) continue to maintain such insurance until performance is completed. The host country government partner shall insert, in all contracts and subcontracts under this agreement, a clause similar to this clause (including this sentence) imposing upon those contractors and subcontractors the obligation to obtain workers' compensation insurance or security as required by HHS/CDC.
- No funds or other support provided under the award may be used for support to any military or paramilitary force or activity, or for support to any police, prison authority, or other security or law enforcement forces without the prior written consent of HHS/CDC.
- **Conscience Clause**

An organization, including a faith-based organization, that is otherwise eligible to receive funds under this agreement for HIV/AIDS prevention, treatment, or care—

 - Shall not be required, as a condition of receiving such assistance—
 - To endorse or utilize a multisectoral or comprehensive approach to combating HIV/AIDS; or
 - To endorse, utilize, make a referral to, become integrated with, or otherwise participate in any program or activity to which the organization has a religious or moral objection; and
 - Shall not be discriminated against in the solicitation or issuance of grants, contracts, or cooperative agreements for refusing to meet any requirement described above.
- **Medically Accurate Information About Condoms**

Information provided about the use of condoms as part of projects or activities funded under the

award must be medically accurate and must include the public health benefits and failure rates of such use.

- **Financing of Terrorism**

Consistent with numerous United Nations Security Council resolutions, including UNSCR 1267 (1999) ([http://www.undemocracy.com/S-RES-1269\(1999\).pdf](http://www.undemocracy.com/S-RES-1269(1999).pdf)), UNSCR 1368 (2001) ([http://www.undemocracy.com/S-RES-1368\(2001\).pdf](http://www.undemocracy.com/S-RES-1368(2001).pdf)), UNSCR 1373 (2001) ([http://www.undemocracy.com/S-RES-1373\(2001\).pdf](http://www.undemocracy.com/S-RES-1373(2001).pdf)), and UNSCR 1989 (2011), both HHS/CDC and the Applicant are firmly committed to the international fight against terrorism, and in particular, against the financing of terrorism. It is the policy of HHS/CDC to seek to ensure that none of its funds are used, directly or indirectly, to provide support to individuals or entities associated with terrorism. In accordance with this policy, the Applicant agrees to use reasonable efforts to ensure that none of the HHS/CDC funds provided under this Agreement are used to provide support to individuals or entities associated with terrorism, including those identified on the U.S. Department of Treasury Office of Foreign Assets Control Specially Designated Nationals List. This provision must be included in all subagreements, including contracts and subawards, issued under this award.

- **Source and Nationality and Other Procurement Restrictions**

- Disbursements will be used exclusively to finance the costs of goods and services required for this Agreement [in accordance with 22 CFR 228, and] having their source and nationality in countries [included in Geographic Code [937 or 935]] OR [identified in subsection 6 below], except as HHS/CDC may otherwise agree in writing and as follows:
 - Ocean transportation costs must be financed under the Agreement only on vessels under flag registry of [countries included in Code 935] OR [the following countries: LIST. Also see subsection 7 below on use of U.S.-flag vessels.
 - Any motor vehicles financed under the Agreement will be of United States manufacture, except as HHS/CDC may otherwise agree in writing.
- The nationality of the contractor providing ocean and air shipping services will be deemed to be the ocean vessel's or aircraft's country of registry at the time of shipment.
- Provisions concerning restricted and ineligible goods and services may be provided in subsequent written communications between the parties. Special procurement rules apply to agricultural commodities, pharmaceuticals, pesticides, and fertilizer, none of which may be procured without advance written consent of HHS/CDC.
- Transportation by air of property or persons financed under this agreement will be on carriers holding United States certification, to the extent service by such carriers is available under the Fly America Act. This requirement may be further described by HHS/CDC in subsequent written communications between the parties.
- Eligibility Date. No goods or services may be financed under the Agreement which are procured pursuant to orders or contracts firmly placed or entered into prior to the date of this Agreement, except as the Parties may otherwise agree in writing.
- Eligible countries for procurement: HHS/CDC to identify for specific agreement.
- Transportation
 - In addition to the requirements in subsection 1 above, costs of ocean or air transportation and related delivery services may not be financed under this Agreement, if the costs are for transportation under an ocean vessel or air charter which has not received prior HHS/CDC approval.
 - Unless HHS/CDC determines that privately owned U.S. -flag commercial ocean vessels are not available at fair and reasonable rates for such vessels, or otherwise agrees in writing:
 - At least fifty percent (50%) of the gross tonnage of all goods (computed

separately for dry bulk carriers, dry cargo liners and tankers) financed by HHS/CDC which may be transported on ocean vessels will be transported on privately owned U.S.-flag commercial vessels; and

- At least fifty percent (50%) of the gross freight revenue generated by all shipments financed by HHS/CDC and transported to the territory of the Grantee on dry cargo liners shall be paid to or for the benefit of privately owned U.S.-flag commercial vessels. Compliance with the requirements of (1) and (2) of this subsection must be achieved with respect to both any cargo transported from U.S. ports and any cargo transported from non-U.S. ports, computed separately.

- **Environmental Impact Statement**

HHS/CDC and the Applicant agree to implement the Project in conformance with the regulatory and legal requirements of the Partner Country's environmental legislation and HHS/CDC's environmental policies.

- The Applicant is required to create and follow an environmental mitigation plan and report (EMPR) for each thematic area covered by this agreement. The EMPR shall include the following:
 - Coversheet;
 - Narrative with project specific information, including level of effort;
 - Annexes:
 - Environmental Screening Form (Table 1);
 - Identification of Mitigation Plan (Table 2);
 - Environmental Monitoring and Tracking Table (Table 3);
 - Photos and Maps, as appropriate.
- The EMPR will capture potential environmental impacts and also inform whether a supplemental Initial Environmental Examination (IEE) is required and should be completed and submitted to HHS/CDC.

- **Branding**

All PEPFAR-funded programs or activities must adhere to PEPFAR branding guidance, which includes guidance on the use of the PEPFAR logo and/or written attribution to PEPFAR. PEPFAR branding guidance can be found at <http://www.pepfar.gov/reports/guidance/branding/index.htm>

- **The 8% Rule**

The President's Emergency Plan for AIDS Relief (PEPFAR) seeks to promote sustainability for programs through the development, use, and strengthening of local partnerships. The diversification of partners also ensures additional robust capacity at the local and national levels.

To achieve this goal, the Office of the Global AIDS Coordinator (OGAC) establishes an annual funding guideline for grants and cooperative agreement planning. Within each annual PEPFAR country budget, OGAC establishes a limit for the total amount of U.S. Government funding for HIV/AIDS activities provided to a single partner organization under all grant and cooperative agreements for that country. For U.S. Government fiscal year (FY) 2015, the limit is no more than 8 percent of the country's FY 2015 PEPFAR program funding (excluding U.S. Government management and staffing costs), or \$2 million, whichever is greater. The total amount of funding to a partner organization includes any PEPFAR funding provided to the partner, whether directly as prime partner or indirectly as sub-grantee. In addition, subject to the exclusion for umbrella awards and drug/commodity costs discussed below, all funds provided to a prime partner, even if passed through to sub-partners, are applicable to the limit. PEPFAR funds provided to an organization under contracts are not applied to the 8 percent/\$2 million single partner ceiling. Single-partner funding limits will be determined by PEPFAR after the submission of the COP(s).

Exclusions from the 8 percent/\$2 million single-partner ceiling are made for (a) umbrella awards, (b) commodity/drug costs, and (c) Government Ministries and parastatal organizations. A parastatal organization is defined as a fully or partially state-owned corporation or government agency. For umbrella awards, grants officers will determine whether an award is an umbrella for purposes of exception from the cap on an award-by-award basis. Grants or cooperative agreements in which the primary objective is for the organization to make sub-awards and at least 75 percent of the grant is used for sub-awards, with the remainder of the grant used for administrative expenses and technical assistance to sub-grantees, will be considered umbrella awards and, therefore, exempted from the cap. Agreements that merely include sub-grants as an activity in implementation of the award but do not meet these criteria will not be considered umbrella awards, and the full amount of the award will count against the cap. All commodity/drug costs will be excluded from partners' funding for the purpose of the cap. The remaining portion of awards, including all overhead/management costs, will be counted against the cap.

Applicants should be aware that evaluation of proposals will include an assessment of grant/cooperative agreement award amounts applicable to the applicant by U.S. Government fiscal year in the relevant country. An applicant whose grants or cooperative agreements have already met or exceeded the maximum, annual single-partner limit may submit an application in response to this FOA. However, applicants whose total PEPFAR funding for this country in a U.S. Government fiscal year exceeds the 8 percent/\$2 million single partner ceiling at the time of award decision will be ineligible to receive an award under this FOA unless the U.S. Global AIDS Coordinator approves an exception to the cap. Applicants must provide in their proposals the dollar value by U.S. Government fiscal year of current grants and cooperative agreements (including sub-grants and sub-agreements) financed by the Emergency Plan, which are for programs in the country(ies) covered by this FOA. For example, the proposal should state that the applicant has \$_____ in FY 2015 grants and cooperative agreements (for as many fiscal years as applicable) in Zambia. For additional information concerning this FOA, please contact the Grants Management Officer for this FOA.

16. Other Submission Requirements:

- a. Electronic Submission:** Applications must be submitted electronically at www.grants.gov. The application package can be downloaded from www.grants.gov. Applicants can complete the application package off-line, and then submit the application by uploading it at www.grants.gov website. All application attachments must be submitted using a PDF file format. Directions for creating PDF files can be found at www.grants.gov. File formats other than PDF may not be readable by PGO TIMS staff.

Applications must be submitted electronically by using the forms and instructions posted for this funding opportunity on www.grants.gov.

If Internet access is not available or if the forms cannot be accessed on-line, applicants may contact the PGO TIMS staff at 770-488-2700 or by e-mail at pgotim@cdc.gov, Monday through Friday, 7:30 am–4:30 pm Eastern Standard Time (EST), except federal government holidays. Electronic applications will be considered successful if they are available to PGO TIMS staff for processing from www.grants.gov on the deadline date.

Do not use "special characters (i.e. %, &, * etc.) on the cover page of your application (form SF 424 – Application for Federal Assistance) as special characters are not recognized by the electronic system. Use of special characters may result in your application being rejected. When copy/paste is used on application documents, the grantee should ensure that text only is pasted. When extra,

blank spaces at the end of the original are pasted into the new document it causes the system to reject the document.

- b. Tracking Number:** Applications submitted through www.grants.gov, are time/date stamped electronically and assigned a tracking number. The Authorized Organization Representative (AOR) will receive an email notice of receipt when www.grants.gov receives the application. The tracking number serves to document that the application has been submitted and initiates the electronic validation process before the application is made available to CDC.
- c. Validation Process:** Application submission is not concluded until successful completion of the validation process. After submission of the application package, applicants will receive a "submission receipt" email generated by www.grants.gov. A second email message to applicants will then be generated by www.grants.gov that will either validate or reject the submitted application package. This validation process may take as long as two (2) business days. Applicants are strongly encouraged to check the status of their application to ensure submission of their package is complete and no submission errors have occurred. Applicants also are strongly encouraged to allocate ample time for filing to guarantee that their application can be submitted and validated by the deadline published in the FOA. Non-validated applications will not be accepted after the published application deadline date.

If you do not receive a "validation" e-mail within two business days of application submission, please contact www.grants.gov. For instructions on how to track your application, refer to the e-mail message generated at the time of application submission or the Application User Guide, Version 3.0, page 57.

- d. Technical Difficulties:** If the applicant encounters technical difficulties with www.grants.gov, the applicant should contact www.grants.gov Customer Service. The www.grants.gov Contact Center is available 24 hours a day, 7 days a week, with the exception of Federal Holidays. You can reach the www.grants.gov Contact Center at 1-800-518-4726 or by email at support@www.grants.gov. Submissions sent by email, fax, CD's or thumb drives of applications will not be accepted. Please note that www.grants.gov is managed by HHS.

If Grants.gov is inoperable and cannot receive applications due to an emergency or other unanticipated event that results in the suspension of government operations (and circumstances preclude advance notification of an extension), then applications must be submitted by the first business day on which government operations resume.

- e. Paper Submission:** If technical difficulties are encountered at www.grants.gov, applicants should call the www.grants.gov Contact Center at 1-800-518-4726 or e-mail them at support@www.grants.gov for assistance. After consulting with the Contact Center, if the technical difficulties remain unresolved and electronic submission is not possible, applicants may e-mail or call CDC GMO/GMS, before the deadline, and request permission to submit a paper application. Such requests are handled on a case-by-case basis.

An applicant's request for permission to submit a paper application must include the following three items:

1. Include the www.grants.gov case number assigned to the inquiry;
2. Describe the difficulties that prevent electronic submission and the efforts taken with the www.grants.gov Contact Center to submit electronically; and

3. Be received via e-mail to the GMS listed below at least three calendar days before the application deadline. Paper applications submitted without prior approval will not be considered. If a paper application is authorized, PGO will advise the applicant of specific instructions for submitting the application (e.g., original and two hard copies of the application by U.S. mail or express delivery service).

E. Application Review Information

1. Review and Selection Process:

Applications will be reviewed in three phases

a. Phase I Review:

All applications will be reviewed initially for completeness by the CDC's Procurement and Grants Office (PGO) staff and will be reviewed jointly for eligibility by the CDC Division of Global HIV/AIDS and PGO. Incomplete applications and applications that are non-responsive to the eligibility criteria will not advance to Phase II review. Applicants will be notified that the application did not meet eligibility and/or published submission requirements.

b. Phase II Review:

N/A

c. Phase III Review:

N/A

2. Anticipated Announcement and Award Dates:

The anticipated announcement date is February 2015. The award date will be April 1, 2015.

F. Award Administration Information

1. Award Notices:

Awardees will receive an electronic copy of the Notice of Award (NoA) from the CDC PGO. The NoA shall be the only binding, authorizing document between the awardee and CDC. The NoA will be signed by an authorized GMO and emailed to the awardee program director.

Any application awarded in response to this FOA will be subject to the DUNS, SAM Registration and Federal Funding Accountability And Transparency Act Of 2006 (FFATA) requirements.

Unsuccessful applicants will receive notification of the results of the application review by email with delivery receipt or by mail.

2. Administrative and National Policy Requirements:

Awardees must comply with the administrative requirements outlined in 45 Code of Federal Regulations (CFR) Part 74 or Part 92, as appropriate. To view brief descriptions of relevant provisions visit the CDC website at: http://www.cdc.gov/od/pgo/funding/grants/additional_req.shtm

The following administrative requirements apply to this project:

Generally applicable administrative requirements (ARs):

- AR-9: Paperwork Reduction Act
- AR-10: Smoke-Free Workplace
- AR-11: Healthy People 2020
- AR-12: Lobbying Restrictions
- AR-13: Prohibition on Use of CDC Funds for Certain Gun Control Activities
- AR-14: Accounting System Requirements
- AR-16: Security Clearance Requirement
- AR-21: Small, Minority, And Women-owned Business
- AR-24: Health Insurance Portability and Accountability Act
- AR-25: Release and Sharing of Data
- AR-26: National Historic Preservation Act of 1966
- AR-29: Compliance with EO13513, "Federal Leadership on Reducing Text Messaging while Driving," October 1, 2009
- AR-30: Compliance with Section 508 of the Rehabilitation Act of 1973
- AR- 32: Executive Order 131410: Promoting Quality and Efficient Health Care in Federal Government (If applicable applicants should be aware of the program's current business needs and how they align with nationally adopted Public Health Information Network (PHIN) standards, services, practices, and policies when implementing, acquiring, and updating public health information systems.)
- AR-33: Plain Writing Act of 2010
- AR-34: Patient Protection and Affordable Care Act (e.g. a tobacco-free campus policy and a lactation policy consistent with S4207)

ARs applicable to HIV/AIDS Awards:

- AR-4: HIV/AIDS Confidentiality Provisions
- AR-5: HIV Program Review Panel
- AR-6: Patient Care

Organization Specific ARs:

- AR-8: Public Health System Reporting (Community-based non-governmental organizations)
- AR-15: Proof of Non-profit Status (Non-profit organizations)
- AR 23: Compliance with 45 C.F.R. Part 87 (Faith-based organizations)

Potentially Applicable Public Policy Requirements

- False or Misleading Information
- Taxes: Certification of Filing and Payment of Taxes
- Fly America Act/ U.S. Flag Air Carriers
- National Environmental Policy Act

Pilot Program for Enhancement of Employee Whistleblower Protections: All applicants will have a condition of award that applies to 48 CFR section 3.908 requiring grantees to inform their employees in writing of employee whistleblower rights and protections under 41. U.S.C 4712 in the predominant native language of the workforce.

If applicable, award recipients will be required to submit an electronic version of the final, peer-reviewed manuscript of any work developed under this award upon acceptance for publication. Additional information will be provided in the award terms.

For more information on the Code of Federal Regulations, visit the National Archives and Records Administration at: <http://www.access.gpo.gov/nara/cfr/cfr-table-search.html>

3. Reporting:

a. CDC Reporting Requirements:

Reporting allows for continuous program monitoring and identifies successes and challenges that awardees encounter throughout the project period. Also, reporting is a requirement for awardees who want to apply for yearly continuation of funding. Reporting helps CDC and awardees because it:

- Helps target support to applicants, particularly for cooperative agreements;
- Provides CDC with periodic data to monitor awardee progress towards meeting the FOA outcomes and overall performance;
- Allows CDC to track performance measures and evaluation findings for continuous program improvement throughout the project period and to determine applicability of evidence-based approaches to different populations, settings, and contexts; and
- Enables the assessment of the overall effectiveness and impact of the FOA.

As described in the following text, awardees must submit an annual performance report, ongoing performance measures data, administrative reports, and a final performance and financial report. A detailed explanation of any additional reporting requirements will be provided in the Notice of Award to successful applicants.

b. Specific Reporting Requirements:

i. Awardee Evaluation and Performance Measurement Plan:

Awardees must provide a more detailed evaluation and performance measurement plan within the first six months of the project. This more detailed plan should be developed by awardees as part of first-year project activities, with support from CDC. This more detailed plan should build on the elements stated in the initial plan, and should be no more than 25 pages. At a minimum, and in addition to the elements of the initial plan, this plan must:

- Indicate the frequency that evaluation and performance data are to be collected.
- Describe how data will be reported.
- Describe how evaluation findings will be used to ensure continuous quality and program improvement.
- Describe how evaluation and performance measurement will yield findings that will demonstrate the value of the FOA (e.g., effect on improving public health outcomes, effectiveness of FOA as it pertains to performance measurement, cost-effectiveness, or cost-benefit).
- Describe dissemination channels and audiences (including public dissemination).
- Describe other information requested and as determined by the CDC program.

When developing evaluation and performance measurement plans, applicants are encouraged to use the Introduction to Program Evaluation for Public Health Programs: A Self-Study Guide, available at: <http://www.cdc.gov/eval/guide/index.htm>

ii. Annual Performance Report:

(due no later than 120 days before the end of the budget period and serves as a continuation application).

This report must not exceed 35 pages excluding work plan and administrative reporting. Attachments are not permitted, but web links are allowed. The awardee must submit the Annual Performance Report via www.grants.gov no later than 120 days before the end of the budget period. In addition, the awardee must submit an annual Federal Financial Report within 90 days after the end of the calendar quarter in which the budget year ends.

This report must include the following:

- **Performance Measures (including outcomes)** – Awardees must report on performance measures for each budget period and update measures, if needed
- **Evaluation Results** – Awardees must report evaluation results for the work completed to date (including any impact data)
- **Work Plan (maximum of 25 pages)** – Awardees should update work plan each budget period
- **Successes**
 - ✓ Awardees must report progress on completing activities outlined in the work plan
 - ✓ Awardees must describe any additional successes (e.g., identified through evaluation results or lessons learned) achieved in the past year
 - ✓ Awardees must describe success stories
- **Challenges**
 - ✓ Awardees should describe any challenges that hinder achievement of both annual and project period outcomes, performance measures, or their ability to complete the activities in the work plan
 - ✓ Awardees must describe any additional challenges (e.g., identified through evaluation results or lessons learned) encountered in the past year
- **CDC Program Support to Awardees**
 - ✓ Awardees should describe how CDC could assist them in overcoming any challenges to achieve both annual and project period outcomes and performance measures, and complete activities outlined in the work plan
- **Administrative Reporting (not subject to page limits)**
 - ✓ SF-424A Budget Information-Non-Construction Programs
 - ✓ Budget Narrative – Must use the format outlined in Section IV. Content and Form

- of Application Submission, Budget Narrative Section
- ✓ Indirect Cost Rate Agreement
- ✓ Pipeline Analysis – Expenditures versus budget as identified in work plan, description of challenges, and explanation of unexpected pipeline (high or low).
- **Measures of Effectiveness**
 - ✓ Include progress against the numerical goals of the President’s Emergency Plan for AIDS Relief for Zambia and HHS/CDC guidance

iii. Performance Measure Reporting:

CDC programs must require awardees to submit performance measures annually at a minimum, and may require reporting more frequently. Performance measure reporting should be limited to the collection of data. When funding is awarded initially, CDC programs should specify reporting frequency, required data fields, and format.

iv. Monitoring Reporting and Evaluation:

CDC programs must ensure that grantee’s Evaluation and Performance Measurement Plan is aligned with the strategic information guidance established by OGAC and other HHS/CDC requirements, including PEPFAR’s Monitoring Reporting and Evaluation (MER) strategy and CDC’s Data for Partner Monitoring Program (DFPM).

v. Federal Financial Reporting:

The annual FFR form (SF-425) is required and must be submitted through eRA Commons² within 90 days after the end of the calendar quarter in which the budget year ends. The report should include only those funds authorized and disbursed during the timeframe covered by the report. The final report must indicate the exact balance of unobligated funds, and may not reflect any unliquidated obligations. The final FFR expenditure data and the Payment Management System’s (PMS) cash transaction data must correspond; no discrepancies between the data sets are permitted. Failure to submit the required information by the due date may affect adversely the future funding of the project. If the information cannot be provided by the due date, awardees are required to submit a letter of explanation and include the date by which the information will be provided.

vi. Final Performance and Financial Report:

At the end of the project period, awardees must submit a final report to include a final financial and performance report. This report is due 90 days after the end of the project period. The page limit for this report is not to exceed 40 pages.

At a minimum, this report must include the following:

- Performance Measures (including outcomes) – Applicants must report final performance data for all performance measures for the project period.
- Evaluation results – Applicants must report final evaluation results for the project period
- Impact of Results – Applicants must describe the effects or results of the work completed over the project period, including success stories.
- Additional forms as described in the Notice of Award, including Equipment Inventory Report and Final Invention Statement.
- FFR (SF-425)

Awardees should e-mail the report to the CDC PO and the GMS listed in the “Agency Contacts”

² <https://commons.era.nih.gov/commons/>

section of the FOA.

4. Federal Funding Accountability and Transparency Act of 2006:

Federal Funding Accountability And Transparency Act Of 2006 (FFATA), Public Law 109-282, the Federal Funding Accountability and Transparency Act of 2006 as amended (FFATA), requires full disclosure of all entities and organizations receiving Federal funds including awards, contracts, loans, other assistance, and payments through a single publicly accessible Web site, www.USASpending.gov.

Compliance with this law is primarily the responsibility of the Federal agency. However, two elements of the law require information to be collected and reported by applicants: 1) information on executive compensation when not already reported through the SAM, and 2) similar information on all sub-awards/subcontracts/consortiums over \$25,000.

For the full text of the requirements under the FFATA and HHS guidelines, go to:

- http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=109_cong_bills&docid=f:s2590enr.txt.pdf,
- https://www.fsrs.gov/documents/ffata_legislation_110_252.pdf
- http://www.hhs.gov/asfr/ogapa/aboutog/Grants%20Management%20Information/ffata_guidelines.html.

5. Programmatic Impact Reporting and Monitoring:

- A. The recipient is responsible for managing and monitoring each project, program, subaward, function or activity supported through this Agreement. Recipients must monitor subawards to ensure that subrecipients have met the programmatic impact requirements as set forth in the subrecipient's agreement.
- B. The recipient must submit the original and two copies of annual and semi-annual Performance reports and semi-annual pipeline analysis reports. Annual reports must be due 90 calendar days after the award year and semi-annual reports must be due 30 days after the reporting period. The final performance reports are due 90 calendar days after the expiration or termination of this Agreement.
- C. Performance reports must generally contain, for each award, brief information on each of the following:
 - A comparison of actual accomplishments with the goals and objectives previously established for the period, including metrics outlined in the monitoring and evaluation plan (section on M&E), any findings of an external entity, or both. Whenever appropriate and the output of programs or projects can be readily quantified, such quantitative data must be included in the reports and be related to cost data for computation of unit costs. Also included should be a brief description of the methods used to assure and assess the quality of the quantitative data, including any remediation taken to improve findings of poor data quality.
 - Reasons why established goals for the performance period were not met, if appropriate.
 - Other pertinent information including, when appropriate, statutory or Congressional reporting requirements, analysis and explanation of cost overruns or high unit costs reported in financial reports.
 - The recipient must immediately notify the awarding agency of developments that have a significant impact on the award-supported activities. Also, recipients must give notification immediately in the case of problems, delays, or adverse conditions which materially impair the ability to meet the objectives of the award. This notification must

include a statement of the action taken or contemplated, and any assistance needed to resolve the situation.

- The Pipeline Analysis report must contain expenditures versus budget as identified in work plan, description of challenges, and explanation of unexpected pipeline (high or low).
- Program Monitoring and Evaluation Indicators as well as jointly agreed process indicators for monitoring of general program implementation. Any constraints or challenges to program implementation must also be indicated.

The recipient is required to submit in a timely manner semi-annual and annual program results for all relevant programmatic indicators in accordance with U.S. government guidance.

6. Monitoring and Evaluation:

- A. The recipient must submit a monitoring and evaluation plan for approval, and carry out monitoring and evaluation activities in accordance with the approved monitoring and evaluation plan. HHS/CDC will review and approve the recipient's monitoring and evaluation plan to ensure that it is appropriate for the activities to be undertaken as part of the agreement, for compliance with the monitoring and evaluation guidance established by HHS/CDC or other guidance otherwise applicable to this Agreement.
- B. HHS/CDC or its designee will also undertake monitoring and evaluation of the defined activities within the agreement. The recipient must ensure reasonable access by HHS/CDC or its designee to all necessary sites, documentation, individuals and information to monitor, evaluate and verify the appropriate implementation the Activities and use of HHS/CDC funding under this Agreement, must require a provision to this effect in all sub-awards or contracts financed by funds under this Agreement. Where applicable, this includes support for, and response to, activities associated with the Site Monitoring System and implementation of Data and Service Quality Assessments.

7. Expenditure Analysis

Recipients of PEPFAR funds are required to report annually on program expenditures. Specifically, annual completion of PEPFAR Program Expenditures (Form DS-4213, approved by OMB 1405-0208, or the relevant OMB-approved format) will be required in conjunction with the PEPFAR Annual Progress Report at the completion of the USG fiscal year.

8. Audit, Books, and Records Clause:

- A. Reports and Information. The recipient must furnish HHS/CDC accounting records and such other information and reports relating to the Agreement as HHS/CDC may reasonably request.
- B. The Recipient Agreement Books and Records. The recipient must maintain accounting books, records, documents and other evidence relating to the Agreement, adequate to show, without limitation, all costs incurred by the recipient, the receipt and use of goods and services acquired by the recipient, agreed-upon cost sharing requirements, the nature and extent of solicitations of prospective suppliers of goods and services acquired by the recipient, the basis of award of recipient contracts and orders, and the overall progress of the Agreement toward completion ("Agreement books and records"). The recipient must maintain Agreement books and records in accordance with generally accepted accounting principles prevailing in the United States, or at the recipient's option, with approval by HHS/CDC, other accounting principles, such as those (1) prescribed by the International Accounting Standards Committee (an affiliate of the International Federation of Accountants), or (2) prevailing in the country of the recipient. Agreement books and records must be maintained for at least three years after the date of last disbursement by HHS/CDC or for such longer period, if any, required to resolve any litigation, claims or audit findings.

- C. Partner Government Audit. If \$300,000 or more of US Government funds are expended by the recipient in its fiscal year under the Agreement, the recipient must have financial audits made of the expenditures in accordance with the following terms, except as the Parties may otherwise agree in writing:
- i. The recipient must use its Supreme Audit Institution (SAI), if the SAI is approved by HHS/CDC, or select an independent auditor to perform the audit in accordance with the guidelines issued by HHS/CDC.
 - ii. The audit must determine whether the receipt and expenditure of the funds provided under the Agreement are presented in accordance with generally accepted accounting principles agreed to in Section 2 above and whether the recipient has complied with the terms of the Agreement. Each audit must be submitted to HHS/CDC no later than nine months after the close of the recipient's year under audit.
- D. Sub-recipient Audits. The recipient, except as the Parties may otherwise agree in writing, must ensure that "covered" sub-recipients, as defined below, are audited, and submit to HHS/CDC, no later than the end of the recipient's year under audit, in form and substance satisfactory to HHS/CDC, a plan for the audit of the expenditures of "covered" sub-recipients, as defined below, that receive funds under this Agreement pursuant to a direct contract or agreement with the recipient.
- i. "Covered" sub-recipient is one who expends \$300,000 or more in its fiscal year in "US Government awards" (i.e. as recipients of US Government cost reimbursable contracts, grants or cooperative agreements).
 - ii. The plan must describe the methodology to be used by the recipient to satisfy its audit responsibilities for covered sub-recipients. The recipient may satisfy such audit responsibilities by relying on independent audits of the sub-recipients; expanding the scope of the independent financial audit of the recipient to encompass testing of sub-recipients' accounts; or a combination of these procedures.
 - iii. The plan must identify the funds made available to sub-recipients that will be covered by audits conducted in accordance with audit provisions that satisfy the recipient's audit responsibilities.
 - iv. The recipient must ensure that covered sub-recipients under direct contracts or agreements with the recipient take appropriate and timely corrective actions; consider whether sub-recipients' audits necessitate adjustment of its own records; and require each such sub-recipient to permit independent auditors to have access to records and financial statements as necessary.
- E. Audit Reports. The recipient must furnish or cause to be furnished to HHS/CDC an audit report for each audit arranged for by the recipient in accordance with this Section within 30 days after completion of the audit and no later than nine months after the end of the period under audit.
- F. Cost of Audits. Subject to HHS/CDC approval in writing, costs of audits performed in accordance with the terms of this Section may be budgeted for, and charged to, the Agreement so long as such costs are allowable, allocable, and reasonable as defined in the Cost Allowability section of this Agreement.
- G. Audit by HHS/CDC. HHS/CDC retains the right to perform the audits required under this Agreement on behalf of the recipient conduct a financial review, or otherwise ensure accountability of organizations expending US Government funds regardless of the audit requirement.
- H. Opportunity to Audit or Inspect. The recipient must afford authorized representatives of HHS/CDC

the opportunity at all reasonable times to audit or inspect activities financed under the Agreement, the utilization of goods and services financed by HHS/CDC, and books, records and other documents relating to the Agreement.

- I. Sub-recipient Books and Records. The recipient will incorporate paragraphs (1), (2), (4), (5), (6), (7) and (8) of this provision into all sub-agreements with non-U.S. organizations which meet the \$300,000 threshold of paragraph (3) of this provision. Sub-agreements with non-U.S. organizations, which do not meet the \$300,000 threshold, must, at a minimum, incorporate paragraphs (7) and (8) of this provision. Sub-agreements with U.S. organizations must state that the U.S. organization is subject to the audit requirements contained in OMB Circular A-133.

9. Reporting of Foreign Taxes

- A. Valued Added Tax (VAT) and Customs Duties – Customs and import duties, consular fees, customs surtax, valued added taxes, and other related charges are hereby authorized as an allowable cost for costs incurred for non-host governmental entities operating where no applicable tax exemption exists. This waiver does not apply to countries where a bilateral agreement (or similar legal document) is already in place providing applicable tax exemptions and it is not applicable to Ministries of Health. Successful applicants will receive information on VAT requirements via their Notice of Award.
- B. The U.S. Department of State requires that agencies collect and report information on the amount of taxes assessed, reimbursed and not reimbursed by a foreign government against commodities financed with funds appropriated by the U.S. Department of State, Foreign Operations and Related Programs Appropriations Act (SFOAA) (“United States foreign assistance funds”). Outlined below are the specifics of this requirement:
 - 1) Annual Report: The grantee must submit a report on or before November 16 for each foreign country on the amount of foreign taxes charged, as of September 30 of the same year, by a foreign government on commodity purchase transactions valued at 500 USD or more financed with United States foreign assistance funds under this grant during the prior United States fiscal year (October 1 – September 30), and the amount reimbursed and unreimbursed by the foreign government. [Reports are required even if the grantee did not pay any taxes during the reporting period.]
 - 2) Quarterly Report: The grantee must quarterly submit a report on the amount of foreign taxes charged by a foreign government on commodity purchase transactions valued at 500 USD or more financed with United States foreign assistance funds under this grant. This report shall be submitted no later than two weeks following the end of each quarter: April 15, July 15, October 15 and January 15.
 - 3) Terms: For purposes of this clause:
 - “Commodity” means any material, article, supplies, goods, or equipment;
 - “Foreign government” includes any foreign government entity;
 - “Foreign taxes” means value-added taxes and custom duties assessed by a foreign government on a commodity. It does not include foreign sales taxes.
 - 4) Where: Submit the reports to the Director and Deputy Director of the CDC office in the country(ies) in which you are carrying out the activities associated with this cooperative agreement. In countries where there is no CDC office, send reports to VATreporting@cdc.gov.

- 5) Contents of Reports: The reports must contain:
- a. grantee name;
 - b. contact name with phone, fax, and e-mail;
 - c. agreement number(s) if reporting by agreement(s);
 - d. reporting period;
 - e. amount of foreign taxes assessed by each foreign government;
 - f. amount of any foreign taxes reimbursed by each foreign government;
 - g. amount of foreign taxes unreimbursed by each foreign government.
- 6) Subagreements. The grantee must include this reporting requirement in all applicable subgrants and other subagreements.

10. Human Subjects Restrictions:

Data collection protocols required for release of human subjects funding restrictions must be submitted to the DGHA Science Office within 6 months of notification of such restrictions, but no later than the end of the first budget year. Requests for exceptions to these deadlines will need to be submitted in writing to the Grants Management Officer.

All protocol approvals should be obtained no later than the end of the subsequent budget period after the award or continuation has been made, provided that the Grantee has not been granted an exception to the deadlines specified above.

G. Agency Contacts

CDC encourages inquiries concerning this announcement.

For **programmatic technical assistance**, contact:

Esther de Gourville, Project Officer
Department of Health and Human Services
Centers for Disease Control and Prevention
351 Independence Avenue,
Lusaka, Zambia
10101
Telephone: 260 211 257515
Email: wjq8@cdc.gov

For financial, awards management, or budget assistance, contact:

Arthur Lusby, Grants Management Officer
Department of Health and Human Services
CDC Procurement and Grants Office
2920 Brandywine Road, MS K75
Atlanta, GA 30341
Telephone: 770-488-2865
Email: cmx3@cdc.gov

For assistance with submission difficulties related to www.grants.gov, contact:

www.grants.gov Contact Center: 1-800-518-4726.

Hours of Operation: 24 hours a day, 7 days a week. Closed on Federal holidays.

For all other submission questions, contact:

Technical Information Management Section

Department of Health and Human Services
CDC Procurement and Grants Office
2920 Brandywine Road, MS E-14
Atlanta, GA 30341
Telephone: 770-488-2700
Email: pgotim@cdc.gov

CDC Telecommunications for individuals with hearing loss is available at: TTY 1.888.232.6348

H. Other Information

Following is a list of acceptable attachments that applicants must upload as PDF files part of their application at www.grants.gov. Applicants may not attach documents other than those listed; if other documents are attached, that document will not be reviewed.

- Project Abstract (required form)
- CDC Assurances and Certifications (required form)
- Table of Contents for Entire Submission (no page limit)
- Project Narrative/Work Plan (maximum 18 pages)
- Budget Narrative (no page limit)
- SF424 (required form)
- SF424A (required form)

Applicants may submit additional information in an Appendix. The appendices will not be counted toward the project narrative page limit. **The total amount of appendices must not exceed 90 pages.** Any pages after page 90 of the appendix will not be considered for review. The following documents must be included in the application appendices:

- **Resumes/CVs of current key staff** who will work on the activity, including, but not limited to: Principal Investigator, Business Official, Project Manager
 - Please refer to Section D, #10, part d, “Organizational Capacity of Awardees to Execute the Approach” for specific job descriptions required in this FOA, as applicable
- **Job Descriptions of proposed key positions** to be created for the activity, including, but not limited to: Principal Investigator, Business Official, Project Manager
 - Please refer to Section D, #10, part d, “Organizational Capacity of Awardees to Execute the Approach” for specific job descriptions required in this FOA, as applicable
- **Letters of support:** See Collaborations section and Funding Preference section, as applicable
- **Memorandums of Understanding/Agreements (MOU/MOA):** See Collaborations section and Funding Preference section, as applicable
- **Organizational Chart**
- **Letters of Intent (LOI),** as applicable
- **Negotiated Indirect Cost Rate Agreement,** if applicable
- **Non-profit organization IRS status forms,** if applicable

Any additional information submitted via www.grants.gov must be uploaded in a PDF file format, and should be clearly labeled (i.e.: Letters of support should be named “letters of support”).

Amendments, Questions and Answers (Q&As)

Applicants must submit their Q&As, if any, to the Project Officer listed under the Agency Contacts Section of this announcement no later than 15 days after the publication date in www.grants.gov. All Q&As will be published on the DGHA Website <http://www.cdc.gov/globalaids/global-hiv-aids-at-cdc/FOA.html>.

All changes, updates, and amendments to the FOA will be posted to www.grants.gov following the approval of

CDC.

For additional information on reporting requirements, visit the CDC website at:
http://www.cdc.gov/od/pgo/funding/grants/additional_req.shtm.

Other CDC funding opportunity announcements can be found on Grants.gov website, at the following internet address: <http://www.grants.gov>.

I. Glossary

Administrative and National Policy Requirements, Additional Requirements (ARs): outline the Administrative requirements found in 45 CFR Part 74 and Part 92 and other requirements as mandated by statute or CDC policy. CDC programs must indicate which ARs are relevant to the FOA. All ARs are listed in the template for CDC programs. Awardees must then comply with the ARs listed in the FOA. To view brief descriptions of relevant provisions visit the CDC website at:
http://www.cdc.gov/od/pgo/funding/grants/additional_req.shtm.

Authority: Legal authorizations that outline the legal basis for the components of each individual FOA. An Office of Global Council (OGC) representative may assist in choosing the authorities appropriate to any given program.

Award: Financial assistance that provides support or stimulation to accomplish a public purpose. Awards include grants and other agreements (e.g., cooperative agreements) in the form of money, or property in lieu of money, by the Federal Government to an eligible recipient.

Budget Period/Year: the duration of each individual funding period within the project period. Traditionally, budget period length is 12 months or 1 year.

Carryover: Unobligated Federal funds remaining at the end of any budget period that, with the approval of the GMO or under an automatic authority, may be carried forward to another budget period to cover allowable costs of that budget period (whether as an offset or additional authorization). Obligated, but unliquidated, funds are not considered carryover.

Catalog of Federal Domestic Assistance (CFDA): A catalog published twice a year which describes domestic assistance programs administered by the federal government. This government-wide compendium of Federal programs lists projects, services, and activities which provide assistance or benefits to the American public.
<https://www.cfda.gov/index?s=agency&mode=form&id=0bebbc3b3261e255dc82002b83094717&tab=programs&tabmode=list&subtab=list&subtabmode=list>

CDC Assurances and Certifications: Standard government-wide grant application forms.

CFDA Number: The CFDA number is a unique number assigned to each program/FOA throughout its lifecycle that enables data and funding tracking and transparency.

Competing Continuation Award: An award of financial assistance which adds funds to a grant and extends one or more budget periods beyond the currently established project period.

Continuous Quality Improvement: A system that seeks to improve the provision of services with an emphasis on future results.

Contracts: An award instrument establishing a binding legal procurement relationship between CDC and a

recipient obligating the latter to furnish a product.

Cooperative Agreement: An award of financial assistance that is used to enter into the same kind of relationship as a grant; and is distinguished from a grant in that it provides for substantial involvement between the Federal agency and the awardee in carrying out the activity contemplated by the award.

Cost Sharing or Matching: Refers to program costs not borne by the Federal government but required of awardees. It may include the value of allowable third-party in-kind contributions, as well as expenditures by the awardee.

Direct Assistance: assistance given to an applicant such as federal personnel or supplies. See http://www.cdc.gov/stltpublichealth/GrantsFunding/direct_assistance.html.

Federal Funding Accountability And Transparency Act Of 2006 (FFATA): Requires information on Federal awards, including awards, contracts, loans, and other assistance and payments, be made available to the public on a single website, www.USAspending.gov.

Fiscal Year: The year that budget dollars are allocated to fund program activities. The fiscal year starts October 1st and goes through September 30th.

Grant: A legal instrument used by the Federal government to enter into a relationship, the principal purpose of which is to transfer anything of value to a recipient to carry out a public purpose of support or stimulation authorized by statute. The financial assistance may be in the form of money, or property in lieu of money. The term does not include: a Federal procurement subject to the Federal Acquisition Regulation; technical assistance (which provides services instead of money); or assistance in the form of revenue sharing, loans, loan guarantees, interest subsidies, insurance, or direct payments of any kind to individuals. The main difference between a grant and a cooperative agreement is that there is no anticipated substantial programmatic involvement by the Federal Government under an award.

Grants.gov: A "storefront" web portal for use in electronic collection of data (forms and reports) for Federal grant-making agencies through the www.grants.gov site, www.grants.gov.

Health Disparities: are differences in health outcomes and their determinants between segments of the population, as defined by social, demographic, environmental, and geographic attributes.

Healthy People 2020: Provides national health objectives for improving the health of all Americans by encouraging collaborations across sectors, guiding individuals toward making informed health decisions, and measuring the impact of prevention activities.

Inclusion: Inclusion refers to both the meaningful involvement of community members in all stages of the program process, and maximum involvement of the target population in the benefits of the intervention. An inclusive process assures that the views, perspectives, and needs of affected communities, care providers, and key partners are actively included.

Indirect Costs: Those costs that are incurred for common or joint objectives and therefore cannot be identified readily and specifically with a particular sponsored project, program, or activity but are nevertheless necessary to the operations of the organization. For example, the costs of operating and maintaining facilities, depreciation, and administrative salaries are generally treated as indirect costs.

International public health work: For purposes of this template, is defined as work conducted internationally for the benefit of a foreign entity or jurisdiction.

Lobbying: Direct lobbying includes any attempt to influence legislation, appropriations, regulations, administrative actions or Executive Orders (“legislation or other orders”), or other similar deliberations at all levels of government through communications that directly express a view on proposed or pending legislation or other orders and which are directed to members of staff, or other employees of a legislative body or to government officials or employees who participate in the formulation of legislation or other orders. Grass Roots lobbying includes efforts directed at inducing or encouraging members of the public to contact their elected representatives at the Federal, State or local levels to urge support of, or opposition to, proposed or pending legislative proposals.

Maintenance of Effort: A requirement contained in authorizing legislation, regulation stating that to receive Federal grant funds a recipient must agree to contribute and maintain a specified level of financial effort for the award from its own resources or other non-Federal sources. This requirement is typically given in terms of meeting a previous base-year dollar amount.

Memorandum of Understanding (MOU)/Memorandum of Agreement (MOA): is a document describing a bilateral or multilateral agreement between parties. It expresses a convergence of will between the parties, indicating an intended common line of action. It is often used in cases where parties either do not imply a legal commitment or in situations where the parties cannot create a legally enforceable agreement.

New FOA: Any FOA that is not a continuation or supplemental award.

Non-Governmental Organization: A non-governmental organization (NGO) is any non-profit, voluntary citizens' group which is organized on a local, national or international level.

Notice of Award: The only binding, authorizing document between the recipient and CDC confirming issue of award funding. The NoA will be signed by an authorized Grants Management Officer, and provided to the recipient fiscal officer identified in the application.

Objective Review: A process that involves the thorough and consistent examination of applications based on an unbiased evaluation of scientific or technical merit or other relevant aspects of the proposal. The review is intended to provide advice to the individuals responsible for making award decisions.

OGC: Office of the General Counsel (OGC) is the legal team for the Department of Health and Human Services (HHS), providing representation and legal advice on a wide range of national issues. OGC supports the development and implementation of HHS's programs by providing legal services to the Secretary of HHS and the organization's various agencies and divisions.

Outcome: The observable benefits or changes for populations and/or public health capabilities that will result from a particular program strategy.

Performance Measures: Performance measurement is the ongoing monitoring and reporting of program accomplishments, particularly progress toward pre-established goals. It is typically conducted by program or agency management. Performance measures may address the type or level of program activities conducted (process), the direct products and services delivered by a program (outputs), or the results of those products and services (outcomes). A “program” may be any activity, project, function, or policy that has an identifiable purpose or set of objectives.

Plain Writing Act of 2010: The Plain Writing Act requires federal agencies to communicate with the public in plain language to make information and communication more accessible and understandable by intended users, especially people with limited health literacy skills or limited English proficiency. www.plainlanguage.gov

Procurement and Grants Office (PGO): PGO is the only entity within CDC which can obligate federal funds. PGO provides non-programmatic management for all CDC financial assistance activities (grants and cooperative agreements) and manages and awards all CDC contracts.

Program Strategies: Public health interventions or public health capabilities.

Program Official: The person responsible for developing the FOA – whether a project officer, program manager, branch chief, division leadership, policy official, center leadership, or similar staff member.

Project Period Outcome: An outcome that will result by the end of the FOA period of funding.

SAM: The System for Award Management (SAM) is the primary vendor database for the U.S. Federal Government. SAM validates applicant information and electronically shares the secure and encrypted data with the Federal agencies' finance offices to facilitate paperless payments through Electronic Funds Transfer (EFT). The SAM stores organizational information, allowing www.grants.gov to verify your identity and to pre-fill organizational information on grant applications.

Statute: An act of a legislature that declares, proscribes, or commands something; a specific law, expressed in writing. A statute is a written law passed by a legislature on the state or federal level. Statutes set forth general propositions of law that courts apply to specific situations.

Statutory Authority: A legal statute that provides the authority to establish a Federal financial assistance program or award.

Technical Assistance: The providing of advice, assistance, and training pertaining to the development, implementation, maintenance, and/or evaluation of programs.

Work Plan: The summary of annual strategies and activities, personnel and/or partners who will complete them, and the timeline for completion. The work plan will outline the details of all necessary activities that will be supported through the approved budget.